# –ñ–∏—Ä–æ—Å–∂–∏–≥–∞—Ç–µ–ª–∏, –ò–Ω—Å—É–ª–∏–Ω –∏ –ê–≥–æ–Ω–∏—Å—Ç—ã –î–æ—Ñ–∞–º–∏–Ω–∞ ‚Äî –ù–∞—É—á–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ

> –î–∞—Ç–∞: 2026-02-12
> –ò—Å—Ç–æ—á–Ω–∏–∫–∏: Wikipedia, PubMed, FDA labels
> –Ø–∑—ã–∫ –æ–ø–∏—Å–∞–Ω–∏–π: —Ä—É—Å—Å–∫–∏–π | –¶–∏—Ç–∞—Ç—ã: English

---

## –ñ–ò–†–û–°–ñ–ò–ì–ê–¢–ï–õ–ò (FAT BURNERS)

---

## 1. –ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª (Clenbuterol)

### Mechanism of Action
- **–°–µ–ª–µ–∫—Ç–∏–≤–Ω—ã–π Œ≤2-–∞–¥—Ä–µ–Ω–æ—Ä–µ—Ü–µ–ø—Ç–æ—Ä–Ω—ã–π –∞–≥–æ–Ω–∏—Å—Ç** ‚Äî —Å—Ç–∏–º—É–ª–∏—Ä—É–µ—Ç Œ≤2-—Ä–µ—Ü–µ–ø—Ç–æ—Ä—ã –≤ –∂–∏—Ä–æ–≤–æ–π —Ç–∫–∞–Ω–∏ –∏ —Å–∫–µ–ª–µ—Ç–Ω—ã—Ö –º—ã—à—Ü–∞—Ö
- –£–≤–µ–ª–∏—á–∏–≤–∞–µ—Ç –±–∞–∑–∞–ª—å–Ω—ã–π –º–µ—Ç–∞–±–æ–ª–∏–∑–º (BMR), –º–∞–∫—Å–∏–º–∞–ª—å–Ω—É—é –ß–°–° –∏ —Ç–µ—Ä–º–æ–≥–µ–Ω–µ–∑
- –°—Ç–∏–º—É–ª–∏—Ä—É–µ—Ç –ª–∏–ø–æ–ª–∏–∑ —á–µ—Ä–µ–∑ –∞–∫—Ç–∏–≤–∞—Ü–∏—é –∞–¥–µ–Ω–∏–ª–∞—Ç—Ü–∏–∫–ª–∞–∑—ã ‚Üí —Ü–ê–ú–§ ‚Üí –ø—Ä–æ—Ç–µ–∏–Ω–∫–∏–Ω–∞–∑–∞ –ê ‚Üí –≥–æ—Ä–º–æ–Ω-—á—É–≤—Å—Ç–≤–∏—Ç–µ–ª—å–Ω–∞—è –ª–∏–ø–∞–∑–∞
- **–ù–ï —è–≤–ª—è–µ—Ç—Å—è –∞–Ω–∞–±–æ–ª–∏–∫–æ–º —É –ª—é–¥–µ–π** ‚Äî –∞–Ω–∞–±–æ–ª–∏—á–µ—Å–∫–∏–µ —Å–≤–æ–π—Å—Ç–≤–∞ –¥–æ–∫–∞–∑–∞–Ω—ã —Ç–æ–ª—å–∫–æ —É –ª–æ—à–∞–¥–µ–π (–ø–æ–≤—ã—à–µ–Ω–Ω–∞—è —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å)
- –ü–µ—Ä–∏–æ–¥ –ø–æ–ª—É–≤—ã–≤–µ–¥–µ–Ω–∏—è: **36‚Äì48 —á–∞—Å–æ–≤** (–æ—á–µ–Ω—å –¥–ª–∏–Ω–Ω—ã–π!)
- –ë–∏–æ–¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å: 89‚Äì98% –ø–µ—Ä–æ—Ä–∞–ª—å–Ω–æ
- –ú–µ—Ç–∞–±–æ–ª–∏–∑–º: –ø–µ—á—ë–Ω–æ—á–Ω—ã–π (–º–∏–Ω–∏–º–∞–ª—å–Ω—ã–π)

### Key Clinical Studies
- **Pluim BM et al., 2011** (PMID: 21142283)
  - Design: Systematic review & meta-analysis of RCTs
  - Key finding: Œ≤2-–∞–≥–æ–Ω–∏—Å—Ç—ã –Ω–µ —É–ª—É—á—à–∞—é—Ç —Ñ–∏–∑–∏—á–µ—Å–∫—É—é –ø—Ä–æ–∏–∑–≤–æ–¥–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å –∑–Ω–∞—á–∏–º–æ; WADA –∫–ª–∞—Å—Å–∏—Ñ–∏—Ü–∏—Ä—É–µ—Ç –∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª –∫–∞–∫ –∞–Ω–∞–±–æ–ª–∏—á–µ—Å–∫–∏–π –∞–≥–µ–Ω—Ç –Ω–µ—Å–º–æ—Ç—Ä—è –Ω–∞ –æ—Ç—Å—É—Ç—Å—Ç–≤–∏–µ –¥–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤
  - Relevance: –û–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ –¥–ª—è off-label –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏—è —Å–ø–æ—Ä—Ç—Å–º–µ–Ω–∞–º–∏
- **Guddat S et al., 2012** (PMID: 22447758)
  - Design: Analytical study, –¥–æ–ø–∏–Ω–≥-–∫–æ–Ω—Ç—Ä–æ–ª—å
  - Key finding: –ó–∞–≥—Ä—è–∑–Ω–µ–Ω–∏–µ –ø–∏—â–µ–≤—ã—Ö –ø—Ä–æ–¥—É–∫—Ç–æ–≤ –∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª–æ–º ‚Äî –ø–æ—Ç–µ–Ω—Ü–∏–∞–ª—å–Ω—ã–π –∏—Å—Ç–æ—á–Ω–∏–∫ –Ω–µ–ø—Ä–µ–¥–Ω–∞–º–µ—Ä–µ–Ω–Ω–æ–≥–æ –¥–æ–ø–∏–Ω–≥–∞
  - Relevance: –ö–æ–Ω—Ç–∞–º–∏–Ω–∞—Ü–∏—è –º—è—Å–∞ –∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª–æ–º ‚Äî —Ä–µ–∞–ª—å–Ω–∞—è –ø—Ä–æ–±–ª–µ–º–∞ (–ö–∏—Ç–∞–π, –ú–µ–∫—Å–∏–∫–∞, –ï–≤—Ä–æ–ø–∞)
- **Velasco-Bejarano B et al., 2022** (PMID: 35132808)
  - Design: Analytical UHPLC-MS/MS study
  - Key finding: –û–±–Ω–∞—Ä—É–∂–µ–Ω–∏–µ –æ—Å—Ç–∞—Ç–∫–æ–≤ –∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª–∞ –≤ –º—è—Å–Ω—ã—Ö –ø—Ä–æ–¥—É–∫—Ç–∞—Ö, —Ä–∏—Å–∫ –Ω–µ–ø—Ä–µ–¥–Ω–∞–º–µ—Ä–µ–Ω–Ω–æ–≥–æ –¥–æ–ø–∏–Ω–≥–∞
  - Relevance: –ü–æ–¥—Ç–≤–µ—Ä–∂–¥–µ–Ω–∏–µ –ø—Ä–æ–¥–æ–ª–∂–∞—é—â–µ–π—Å—è –ø—Ä–æ–±–ª–µ–º—ã –∫–æ–Ω—Ç–∞–º–∏–Ω–∞—Ü–∏–∏

### Bloodwork Markers to Monitor
- **–ß–°–° / –ê–î** ‚Äî –ø–æ—Å—Ç–æ—è–Ω–Ω—ã–π –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ (—Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è ‚Äî –æ—Å–Ω–æ–≤–Ω–æ–π –ø–æ–±–æ—á–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç)
- **–ö–∞–ª–∏–π (K+)** ‚Äî –∫–∞–∂–¥—ã–µ 2 –Ω–µ–¥–µ–ª–∏ (Œ≤2-–∞–≥–æ–Ω–∏—Å—Ç—ã –≤—ã–∑—ã–≤–∞—é—Ç –≥–∏–ø–æ–∫–∞–ª–∏–µ–º–∏—é)
- **–ú–∞–≥–Ω–∏–π (Mg)** ‚Äî –∫–∞–∂–¥—ã–µ 2 –Ω–µ–¥–µ–ª–∏
- **–¢–∞—É—Ä–∏–Ω** ‚Äî Œ≤2-–∞–≥–æ–Ω–∏—Å—Ç—ã –∏—Å—Ç–æ—â–∞—é—Ç —Ç–∞—É—Ä–∏–Ω (—Å—É–¥–æ—Ä–æ–≥–∏)
- **–¢—Ä–æ–ø–æ–Ω–∏–Ω / –ö–§–ö-–ú–í** ‚Äî –ø—Ä–∏ –ø–æ–¥–æ–∑—Ä–µ–Ω–∏–∏ –Ω–∞ –∫–∞—Ä–¥–∏–æ—Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å
- **–¢–¢–ì / –¢3 / –¢4** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏ (–º–æ–∂–µ—Ç –≤—ã–∑–≤–∞—Ç—å —Ç–∏—Ä–µ–æ—Ç–æ–∫—Å–∏–∫–æ–∑)
- **–ì–ª—é–∫–æ–∑–∞** ‚Äî –º–æ–∂–µ—Ç –≤—ã–∑–≤–∞—Ç—å –≥–∏–ø–µ—Ä–≥–ª–∏–∫–µ–º–∏—é

### Drug Interactions
- ‚ö†Ô∏è **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + –¥—Ä—É–≥–∏–µ Œ≤-–∞–≥–æ–Ω–∏—Å—Ç—ã (—Å–∞–ª—å–±—É—Ç–∞–º–æ–ª)** ‚Üí –∞–¥–¥–∏—Ç–∏–≤–Ω–∞—è —Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è, –∞—Ä–∏—Ç–º–∏—è
- ‚ö†Ô∏è **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + T3/T4** ‚Üí —Å–∏–Ω–µ—Ä–≥–∏—á–µ—Å–∫–∏–π —Ç–µ—Ä–º–æ–≥–µ–Ω–µ–∑, –ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô —Ä–∏—Å–∫ –∫–∞—Ä–¥–∏–æ—Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç–∏
- ‚ö†Ô∏è **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + –∫–æ—Ñ–µ–∏–Ω/—ç—Ñ–µ–¥—Ä–∏–Ω** ‚Üí —á—Ä–µ–∑–º–µ—Ä–Ω–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è –¶–ù–° + —Å–µ—Ä–¥—Ü–∞
- ‚ö†Ô∏è **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + –ò–ú–ê–û** ‚Üí –≥–∏–ø–µ—Ä—Ç–æ–Ω–∏—á–µ—Å–∫–∏–π –∫—Ä–∏–∑
- ‚ö†Ô∏è **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + –≥–∞–ª–æ—Ç–∞–Ω (–∞–Ω–µ—Å—Ç–µ—Ç–∏–∫)** ‚Üí –∞—Ä–∏—Ç–º–∏—è, –°–ú–ï–†–¢–¨ (–¥–æ–∫—É–º–µ–Ω—Ç–∏—Ä–æ–≤–∞–Ω–Ω—ã–π —Å–ª—É—á–∞–π 2021, –ú–µ–∫—Å–∏–∫–∞)
- **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + Œ≤-–±–ª–æ–∫–∞—Ç–æ—Ä—ã** ‚Üí –≤–∑–∞–∏–º–Ω–∞—è –Ω–µ–π—Ç—Ä–∞–ª–∏–∑–∞—Ü–∏—è

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** —Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è, –∞—Ä–∏—Ç–º–∏–∏, –∏—à–µ–º–∏—á–µ—Å–∫–∞—è –±–æ–ª–µ–∑–Ω—å —Å–µ—Ä–¥—Ü–∞, —Å—É–±–∞–æ—Ä—Ç–∞–ª—å–Ω—ã–π —Å—Ç–µ–Ω–æ–∑, –≥–∏–ø–µ—Ä—Ç–∏—Ä–µ–æ–∑, —Ñ–µ–æ—Ö—Ä–æ–º–æ—Ü–∏—Ç–æ–º–∞
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** –≥–∏–ø–µ—Ä—Ç–æ–Ω–∏—è, —Å–∞—Ö–∞—Ä–Ω—ã–π –¥–∏–∞–±–µ—Ç, —Å—É–¥–æ—Ä–æ–∂–Ω—ã–µ —Ä–∞—Å—Å—Ç—Ä–æ–π—Å—Ç–≤–∞, –ø–æ–∂–∏–ª–æ–π –≤–æ–∑—Ä–∞—Å—Ç

### Practical Notes
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ:** –ù–∞—á–∞–ª–æ 20 –º–∫–≥/–¥–µ–Ω—å, —Ç–∏—Ç—Ä–∞—Ü–∏—è –ø–æ 20 –º–∫–≥ –∫–∞–∂–¥—ã–µ 2‚Äì3 –¥–Ω—è, –º–∞–∫—Å ~120 –º–∫–≥/–¥–µ–Ω—å
- **–°—Ö–µ–º–∞ 2 on / 2 off** (2 –Ω–µ–¥–µ–ª–∏ –ø—Ä–∏—ë–º / 2 –Ω–µ–¥–µ–ª–∏ –ø–µ—Ä–µ—Ä—ã–≤) ‚Äî –∏–∑-–∑–∞ –¥–∞—É–Ω—Ä–µ–≥—É–ª—è—Ü–∏–∏ Œ≤-—Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤
- –ê–ª—å—Ç–µ—Ä–Ω–∞—Ç–∏–≤–Ω–∞—è —Å—Ö–µ–º–∞: –Ω–µ–ø—Ä–µ—Ä—ã–≤–Ω–æ —Å –∫–µ—Ç–æ—Ç–∏—Ñ–µ–Ω–æ–º (1‚Äì2 –º–≥ –Ω–∞ –Ω–æ—á—å) –¥–ª—è —Ä–µ—Å–µ–Ω—Å–∏—Ç–∏–∑–∞—Ü–∏–∏ Œ≤-—Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤
- –°—É–¥–æ—Ä–æ–≥–∏ ‚Äî –¥–æ–±–∞–≤–∏—Ç—å —Ç–∞—É—Ä–∏–Ω (3‚Äì5 –≥/–¥–µ–Ω—å) –∏ –∫–∞–ª–∏–π
- **–ù–ï –æ–¥–æ–±—Ä–µ–Ω FDA –¥–ª—è –ª—é–¥–µ–π** ‚Äî –Ω–µ–ª–µ–≥–∞–ª–µ–Ω –¥–ª—è –ø–∏—â–µ–≤—ã—Ö –∂–∏–≤–æ—Ç–Ω—ã—Ö –≤ –°–®–ê, –ï–°, –ö–∏—Ç–∞–µ
- –¢—Ä–µ–º–æ—Ä —Ä—É–∫ ‚Äî –Ω–∞–∏–±–æ–ª–µ–µ —á–∞—Å—Ç—ã–π –ø–æ–±–æ—á–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç

---

## 2. –õ–∏–æ—Ç–∏—Ä–æ–Ω–∏–Ω / T3 (Liothyronine / Cytomel)

### Mechanism of Action
- **–°–∏–Ω—Ç–µ—Ç–∏—á–µ—Å–∫–∞—è —Ñ–æ—Ä–º–∞ —Ç—Ä–∏–π–æ–¥—Ç–∏—Ä–æ–Ω–∏–Ω–∞ (–¢3)** ‚Äî –Ω–∞–∏–±–æ–ª–µ–µ –∞–∫—Ç–∏–≤–Ω—ã–π —Ç–∏—Ä–µ–æ–∏–¥–Ω—ã–π –≥–æ—Ä–º–æ–Ω
- –°–≤—è–∑—ã–≤–∞–µ—Ç—Å—è —Å —è–¥–µ—Ä–Ω—ã–º–∏ —Ç–∏—Ä–µ–æ–∏–¥–Ω—ã–º–∏ —Ä–µ—Ü–µ–ø—Ç–æ—Ä–∞–º–∏ (TRŒ±, TRŒ≤) ‚Üí —Ä–µ–≥—É–ª—è—Ü–∏—è —Ç—Ä–∞–Ω—Å–∫—Ä–∏–ø—Ü–∏–∏ –≥–µ–Ω–æ–≤
- –ü–æ–≤—ã—à–∞–µ—Ç –±–∞–∑–∞–ª—å–Ω—ã–π –º–µ—Ç–∞–±–æ–ª–∏–∑–º, —Å–∏–Ω—Ç–µ–∑ –±–µ–ª–∫–∞, —á—É–≤—Å—Ç–≤–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å –∫ –∫–∞—Ç–µ—Ö–æ–ª–∞–º–∏–Ω–∞–º
- –†–µ–≥—É–ª–∏—Ä—É–µ—Ç –º–µ—Ç–∞–±–æ–ª–∏–∑–º –±–µ–ª–∫–æ–≤, –∂–∏—Ä–æ–≤ –∏ —É–≥–ª–µ–≤–æ–¥–æ–≤
- 25 –º–∫–≥ T3 ‚âà 100 –º–∫–≥ –ª–µ–≤–æ—Ç–∏—Ä–æ–∫—Å–∏–Ω–∞ (T4)
- –ü–µ—Ä–∏–æ–¥ –ø–æ–ª—É–≤—ã–≤–µ–¥–µ–Ω–∏—è: **2.5 –¥–Ω—è** (–∫–æ—Ä–æ—á–µ —á–µ–º T4)
- –°–≤—è–∑—ã–≤–∞–Ω–∏–µ —Å –±–µ–ª–∫–∞–º–∏ –ø–ª–∞–∑–º—ã: 99.7%

### Key Clinical Studies
- **Klubo-Gwiezdzinska J, Wartofsky L, 2012** (PMID: 22443982)
  - Design: Review, thyroid emergencies
  - Key finding: –õ–∏–æ—Ç–∏—Ä–æ–Ω–∏–Ω –ø—Ä–µ–¥–ø–æ—á—Ç–∏—Ç–µ–ª–µ–Ω –ø—Ä–∏ –º–∏–∫—Å–µ–¥–µ–º–∞—Ç–æ–∑–Ω–æ–π –∫–æ–º–µ –∏–∑-–∑–∞ –±—ã—Å—Ç—Ä–æ–≥–æ –Ω–∞—á–∞–ª–∞ –¥–µ–π—Å—Ç–≤–∏—è
  - Relevance: –ü–æ–∫–∞–∑—ã–≤–∞–µ—Ç —Ñ–∞—Ä–º–∞–∫–æ–∫–∏–Ω–µ—Ç–∏—á–µ—Å–∫–æ–µ –ø—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–æ T3 –Ω–∞–¥ T4
- **Altshuler LL et al., 2001** (PMID: 11578993)
  - Design: Review & meta-analysis
  - Key finding: –î–æ–±–∞–≤–ª–µ–Ω–∏–µ T3 –∫ —Ç—Ä–∏—Ü–∏–∫–ª–∏—á–µ—Å–∫–∏–º –∞–Ω—Ç–∏–¥–µ–ø—Ä–µ—Å—Å–∞–Ω—Ç–∞–º —É—Å–∫–æ—Ä—è–µ—Ç –æ—Ç–≤–µ—Ç, –æ—Å–æ–±–µ–Ω–Ω–æ —É –∂–µ–Ω—â–∏–Ω
  - Relevance: –ù–µ–π—Ä–æ–º–µ—Ç–∞–±–æ–ª–∏—á–µ—Å–∫–∏–µ —ç—Ñ—Ñ–µ–∫—Ç—ã T3
- **Gaynes BN et al., 2008** (PMID: 18236731)
  - Design: STAR*D trial analysis
  - Key finding: –õ–∏–æ—Ç–∏—Ä–æ–Ω–∏–Ω —Ä–µ–∫–æ–º–µ–Ω–¥–æ–≤–∞–Ω –∫–∞–∫ –æ–ø—Ü–∏—è –ø—Ä–∏ –Ω–µ—ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ 2 –∞–Ω—Ç–∏–¥–µ–ø—Ä–µ—Å—Å–∞–Ω—Ç–æ–≤
  - Relevance: –ù–µ–π—Ä–æ–≥–µ–Ω–µ–∑ –≤ –¶–ù–° –ø—Ä–∏ –∫–æ–º–±–∏–Ω–∞—Ü–∏–∏ —Å SSRI
- **Rosenthal LJ et al., 2011** (PMID: 21969047)
  - Design: Review, safety of T3 augmentation in depression
  - Key finding: T3 –∞—É–≥–º–µ–Ω—Ç–∞—Ü–∏—è –≤ —Ü–µ–ª–æ–º –±–µ–∑–æ–ø–∞—Å–Ω–∞ –ø—Ä–∏ –ø—Ä–∞–≤–∏–ª—å–Ω–æ–º –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥–µ
  - Relevance: –ü—Ä–æ—Ñ–∏–ª—å –±–µ–∑–æ–ø–∞—Å–Ω–æ—Å—Ç–∏ –ø—Ä–∏ off-label –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–∏

### Bloodwork Markers to Monitor
- **–¢–¢–ì** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏ (–±—É–¥–µ—Ç –ø–æ–¥–∞–≤–ª–µ–Ω –ø—Ä–∏ —ç–∫–∑–æ–≥–µ–Ω–Ω–æ–º T3)
- **—Å–≤–æ–±–æ–¥–Ω—ã–π T3** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏ (—Ü–µ–ª–µ–≤–æ–π –¥–∏–∞–ø–∞–∑–æ–Ω)
- **—Å–≤–æ–±–æ–¥–Ω—ã–π T4** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏ (–±—É–¥–µ—Ç —Å–Ω–∏–∂–µ–Ω)
- **–û–±—â–∏–π —Ö–æ–ª–µ—Å—Ç–µ—Ä–∏–Ω / –õ–ü–ù–ü / –õ–ü–í–ü** ‚Äî –∫–∞–∂–¥—ã–µ 8 –Ω–µ–¥–µ–ª—å
- **–ö–∞–ª—å—Ü–∏–π / –º–∞—Ä–∫—ë—Ä—ã –∫–æ—Å—Ç–Ω–æ–≥–æ –º–µ—Ç–∞–±–æ–ª–∏–∑–º–∞** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞ (–∏–∑–±—ã—Ç–æ–∫ T3 ‚Üí –æ—Å—Ç–µ–æ–ø–æ—Ä–æ–∑)
- **–ß–°–° / –≠–ö–ì** ‚Äî —Ä–µ–≥—É–ª—è—Ä–Ω–æ (–∞—Ä–∏—Ç–º–∏–∏)
- **–ú–∞—Å—Å–∞ —Ç–µ–ª–∞** ‚Äî –∫–æ–Ω—Ç—Ä–æ–ª—å –ø–æ—Ç–µ—Ä–∏ –º—ã—à–µ—á–Ω–æ–π –º–∞—Å—Å—ã

### Drug Interactions
- ‚ö†Ô∏è **T3 + —Å–∏–º–ø–∞—Ç–æ–º–∏–º–µ—Ç–∏–∫–∏ (–∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª, —ç—Ñ–µ–¥—Ä–∏–Ω, –∫–æ—Ñ–µ–∏–Ω)** ‚Üí –ö–†–ò–¢–ò–ß–ï–°–ö–ê–Ø –∫–∞—Ä–¥–∏–æ—Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å, —Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è, –∞—Ä–∏—Ç–º–∏–∏
- ‚ö†Ô∏è **T3 + –∞–Ω—Ç–∏–∫–æ–∞–≥—É–ª—è–Ω—Ç—ã (–≤–∞—Ä—Ñ–∞—Ä–∏–Ω)** ‚Üí —É—Å–∏–ª–µ–Ω–∏–µ –∞–Ω—Ç–∏–∫–æ–∞–≥—É–ª—è–Ω—Ç–Ω–æ–≥–æ —ç—Ñ—Ñ–µ–∫—Ç–∞
- ‚ö†Ô∏è **T3 + –∏–Ω—Å—É–ª–∏–Ω / –ø–µ—Ä–æ—Ä–∞–ª—å–Ω—ã–µ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—á–µ—Å–∫–∏–µ** ‚Üí —Å–Ω–∏–∂–µ–Ω–∏–µ —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ (T3 –ø–æ–≤—ã—à–∞–µ—Ç –≥–ª—é–∫–æ–∑—É)
- **T3 + —Ö–æ–ª–µ—Å—Ç–∏—Ä–∞–º–∏–Ω / –∫–æ–ª–µ—Å—Ç–∏–ø–æ–ª** ‚Üí —Å–Ω–∏–∂–µ–Ω–∏–µ –∞–±—Å–æ—Ä–±—Ü–∏–∏ T3
- **T3 + —ç—Å—Ç—Ä–æ–≥–µ–Ω—ã** ‚Üí –ø–æ–≤—ã—à–µ–Ω–∏–µ —Å–≤—è–∑—ã–≤–∞—é—â–∏—Ö –±–µ–ª–∫–æ–≤ ‚Üí —Å–Ω–∏–∂–µ–Ω–∏–µ —Å–≤–æ–±–æ–¥–Ω–æ–≥–æ T3

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** –Ω–µ–ª–µ—á–µ–Ω–Ω—ã–π —Ç–∏—Ä–µ–æ—Ç–æ–∫—Å–∏–∫–æ–∑, –Ω–µ–ª–µ—á–µ–Ω–Ω–∞—è –Ω–∞–¥–ø–æ—á–µ—á–Ω–∏–∫–æ–≤–∞—è –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å, –æ—Å—Ç—Ä—ã–π –∏–Ω—Ñ–∞—Ä–∫—Ç –º–∏–æ–∫–∞—Ä–¥–∞
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** —Å–µ—Ä–¥–µ—á–Ω–æ-—Å–æ—Å—É–¥–∏—Å—Ç—ã–µ –∑–∞–±–æ–ª–µ–≤–∞–Ω–∏—è, –ø–æ–∂–∏–ª–æ–π –≤–æ–∑—Ä–∞—Å—Ç, –æ—Å—Ç–µ–æ–ø–æ—Ä–æ–∑, —Å–∞—Ö–∞—Ä–Ω—ã–π –¥–∏–∞–±–µ—Ç
- **FDA Black Box Warning:** –ù–ï –∏—Å–ø–æ–ª—å–∑–æ–≤–∞—Ç—å –¥–ª—è –ª–µ—á–µ–Ω–∏—è –æ–∂–∏—Ä–µ–Ω–∏—è. –î–æ–∑—ã –≤ —ç—É—Ç–∏—Ä–µ–æ–∏–¥–Ω–æ–º –¥–∏–∞–ø–∞–∑–æ–Ω–µ –Ω–µ—ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω—ã –¥–ª—è —Å–Ω–∏–∂–µ–Ω–∏—è –≤–µ—Å–∞. –ë–æ–ª—å—à–∏–µ –¥–æ–∑—ã ‚Üí —Å–µ—Ä—å—ë–∑–Ω–∞—è —Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å, –û–°–û–ë–ï–ù–ù–û –≤ –∫–æ–º–±–∏–Ω–∞—Ü–∏–∏ —Å —Å–∏–º–ø–∞—Ç–æ–º–∏–º–µ—Ç–∏–∫–∞–º–∏

### Practical Notes
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ (–±–æ–¥–∏–±–∏–ª–¥–∏–Ω–≥):** –ù–∞—á–∞–ª–æ 25 –º–∫–≥/–¥–µ–Ω—å, —Ç–∏—Ç—Ä–∞—Ü–∏—è –ø–æ 12.5 –º–∫–≥ –∫–∞–∂–¥—ã–µ 3‚Äì5 –¥–Ω–µ–π, –º–∞–∫—Å 75‚Äì100 –º–∫–≥/–¥–µ–Ω—å
- **–¢–∏–ø–∏—á–Ω—ã–π –∫—É—Ä—Å:** 6‚Äì8 –Ω–µ–¥–µ–ª—å —Å –ø–ª–∞–≤–Ω–æ–π –æ—Ç–º–µ–Ω–æ–π (–æ–±—Ä–∞—Ç–Ω–∞—è —Ç–∏—Ç—Ä–∞—Ü–∏—è)
- –û–±—è–∑–∞—Ç–µ–ª—å–Ω–æ –ü–õ–ê–í–ù–ê–Ø –û–¢–ú–ï–ù–ê ‚Äî —Ä–µ–∑–∫–∞—è –æ—Ç–º–µ–Ω–∞ ‚Üí —Ç—è–∂—ë–ª—ã–π –≥–∏–ø–æ—Ç–∏—Ä–µ–æ–∑ (—Å–æ–±—Å—Ç–≤–µ–Ω–Ω–∞—è –≤—ã—Ä–∞–±–æ—Ç–∫–∞ –ø–æ–¥–∞–≤–ª–µ–Ω–∞)
- –ü—Ä–∏ –∫—É—Ä—Å–µ –ê–ê–°: T3 –ø–æ–º–æ–≥–∞–µ—Ç –∫–æ–º–ø–µ–Ω—Å–∏—Ä–æ–≤–∞—Ç—å –∑–∞–º–µ–¥–ª–µ–Ω–∏–µ –º–µ—Ç–∞–±–æ–ª–∏–∑–º–∞
- –ö–∞—Ç–∞–±–æ–ª–∏–∑–∏—Ä—É–µ—Ç –º—ã—à–µ—á–Ω—É—é —Ç–∫–∞–Ω—å –ø—Ä–∏ –≤—ã—Å–æ–∫–∏—Ö –¥–æ–∑–∞—Ö ‚Üí –∏—Å–ø–æ–ª—å–∑–æ–≤–∞—Ç—å —Ç–æ–ª—å–∫–æ —Å –¥–æ—Å—Ç–∞—Ç–æ—á–Ω—ã–º –±–µ–ª–∫–æ–º –∏ –ê–ê–°
- –î–µ–ª–∏—Ç—å –¥–æ–∑—É –Ω–∞ 2‚Äì3 –ø—Ä–∏—ë–º–∞ (–∫–æ—Ä–æ—Ç–∫–∏–π –ø–µ—Ä–∏–æ–¥ –ø–æ–ª—É–≤—ã–≤–µ–¥–µ–Ω–∏—è)

---

## 3. –°–µ–º–∞–≥–ª—É—Ç–∏–¥ (Semaglutide / Ozempic / Wegovy)

### Mechanism of Action
- **–ê–≥–æ–Ω–∏—Å—Ç —Ä–µ—Ü–µ–ø—Ç–æ—Ä–∞ GLP-1 (–≥–ª—é–∫–∞–≥–æ–Ω–æ–ø–æ–¥–æ–±–Ω–æ–≥–æ –ø–µ–ø—Ç–∏–¥–∞-1)** ‚Äî –º–æ–¥–∏—Ñ–∏—Ü–∏—Ä–æ–≤–∞–Ω–Ω—ã–π –ø–µ–ø—Ç–∏–¥ —Å –∂–∏—Ä–Ω–æ–∫–∏—Å–ª–æ—Ç–Ω–æ–π –±–æ–∫–æ–≤–æ–π —Ü–µ–ø—å—é
- –ú–∏–º–∏–∫—Ä–∏—Ä—É–µ—Ç GLP-1 ‚Üí —Å—Ç–∏–º—É–ª–∏—Ä—É–µ—Ç –∏–Ω—Å—É–ª–∏–Ω, –ø–æ–¥–∞–≤–ª—è–µ—Ç –≥–ª—é–∫–∞–≥–æ–Ω
- –£—Å–∏–ª–∏–≤–∞–µ—Ç —Ä–æ—Å—Ç Œ≤-–∫–ª–µ—Ç–æ–∫ –ø–æ–¥–∂–µ–ª—É–¥–æ—á–Ω–æ–π –∂–µ–ª–µ–∑—ã
- –°–Ω–∏–∂–∞–µ—Ç –∞–ø–ø–µ—Ç–∏—Ç, –∑–∞–º–µ–¥–ª—è–µ—Ç –æ–ø–æ—Ä–æ–∂–Ω–µ–Ω–∏–µ –∂–µ–ª—É–¥–∫–∞
- –¶–µ–Ω—Ç—Ä–∞–ª—å–Ω–æ–µ –¥–µ–π—Å—Ç–≤–∏–µ –Ω–∞ –≥–∏–ø–æ—Ç–∞–ª–∞–º—É—Å ‚Äî —á—É–≤—Å—Ç–≤–æ –Ω–∞—Å—ã—â–µ–Ω–∏—è
- –ü–µ—Ä–∏–æ–¥ –ø–æ–ª—É–≤—ã–≤–µ–¥–µ–Ω–∏—è: **7 –¥–Ω–µ–π** (–ø/–∫ –∏–Ω—ä–µ–∫—Ü–∏—è 1 —Ä–∞–∑ –≤ –Ω–µ–¥–µ–ª—é)
- –ë–∏–æ–¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å: 89% –ø/–∫, 1‚Äì2% –ø–µ—Ä–æ—Ä–∞–ª—å–Ω–æ

### Key Clinical Studies
- **SUSTAIN trials series (diabetes)**
  - –ú–∞—Å—à—Ç–∞–±–Ω–∞—è –ø—Ä–æ–≥—Ä–∞–º–º–∞ –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏—Ö –∏—Å–ø—ã—Ç–∞–Ω–∏–π, –≤–∫–ª—é—á–∞—è SUSTAIN 1-10
  - –°–Ω–∏–∂–µ–Ω–∏–µ HbA1c –Ω–∞ 1.5‚Äì1.8%, —Å–Ω–∏–∂–µ–Ω–∏–µ –≤–µ—Å–∞ 4‚Äì6 –∫–≥ vs –ø–ª–∞—Ü–µ–±–æ
- **STEP trials series (obesity)**
  - STEP 1: —Å–Ω–∏–∂–µ–Ω–∏–µ –≤–µ—Å–∞ ~15% –æ—Ç –∏—Å—Ö–æ–¥–Ω–æ–≥–æ –ø—Ä–∏ 2.4 –º–≥/–Ω–µ–¥ –∑–∞ 68 –Ω–µ–¥–µ–ª—å
  - STEP 2: —É –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ —Å –°–î2 —Å–Ω–∏–∂–µ–Ω–∏–µ ~10%
- **SELECT trial (cardiovascular)**
  - Design: RCT, N>17000, –ø–∞—Ü–∏–µ–Ω—Ç—ã —Å –æ–∂–∏—Ä–µ–Ω–∏–µ–º –∏ –°–°–ó
  - Key finding: 20% —Å–Ω–∏–∂–µ–Ω–∏–µ MACE (major adverse cardiovascular events)
  - Relevance: –ü–µ—Ä–≤—ã–π GLP-1 RA —Å –¥–æ–∫–∞–∑–∞–Ω–Ω—ã–º –∫–∞—Ä–¥–∏–æ–ø—Ä–æ—Ç–µ–∫—Ç–∏–≤–Ω—ã–º —ç—Ñ—Ñ–µ–∫—Ç–æ–º –ø—Ä–∏ –æ–∂–∏—Ä–µ–Ω–∏–∏ –±–µ–∑ –¥–∏–∞–±–µ—Ç–∞
- –ü–æ—Å–ª–µ –æ—Ç–º–µ–Ω—ã: –≤ —Å—Ä–µ–¥–Ω–µ–º –≤–æ–∑–≤—Ä–∞—Ç ~67% –ø–æ—Ç–µ—Ä—è–Ω–Ω–æ–≥–æ –≤–µ—Å–∞ –≤ —Ç–µ—á–µ–Ω–∏–µ –≥–æ–¥–∞

### Bloodwork Markers to Monitor
- **HbA1c / –≥–ª—é–∫–æ–∑–∞ –Ω–∞—Ç–æ—â–∞–∫** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–ê–º–∏–ª–∞–∑–∞ / –ª–∏–ø–∞–∑–∞** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞ (—Ä–∏—Å–∫ –ø–∞–Ω–∫—Ä–µ–∞—Ç–∏—Ç–∞)
- **–§—É–Ω–∫—Ü–∏—è –ø–æ—á–µ–∫ (–∫—Ä–µ–∞—Ç–∏–Ω–∏–Ω, –°–ö–§)** ‚Äî –∫–∞–∂–¥—ã–µ 3‚Äì6 –º–µ—Å—è—Ü–µ–≤
- **–¢–∏—Ä–µ–æ–∏–¥–Ω—ã–µ –º–∞—Ä–∫—ë—Ä—ã (–¢–¢–ì, –∫–∞–ª—å—Ü–∏—Ç–æ–Ω–∏–Ω)** ‚Äî –∫–∞–∂–¥—ã–µ 6 –º–µ—Å—è—Ü–µ–≤ (C-–∫–ª–µ—Ç–æ—á–Ω—ã–µ –æ–ø—É—Ö–æ–ª–∏ —É –≥—Ä—ã–∑—É–Ω–æ–≤)
- **–ü–µ—á—ë–Ω–æ—á–Ω—ã–µ —Ñ–µ—Ä–º–µ–Ω—Ç—ã (–ê–õ–¢, –ê–°–¢)** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–ß–°–°** ‚Äî –º–æ–∂–µ—Ç –Ω–µ–∑–Ω–∞—á–∏—Ç–µ–ª—å–Ω–æ –ø–æ–≤—ã—à–∞—Ç—å—Å—è

### Drug Interactions
- **–°–µ–º–∞–≥–ª—É—Ç–∏–¥ + –∏–Ω—Å—É–ª–∏–Ω / —Å—É–ª—å—Ñ–æ–Ω–∏–ª–º–æ—á–µ–≤–∏–Ω–∞** ‚Üí –ø–æ–≤—ã—à–µ–Ω–Ω—ã–π —Ä–∏—Å–∫ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏ (—Å–Ω–∏–∂–∞—Ç—å –¥–æ–∑—É –∏–Ω—Å—É–ª–∏–Ω–∞)
- **–°–µ–º–∞–≥–ª—É—Ç–∏–¥ + –ø–µ—Ä–æ—Ä–∞–ª—å–Ω—ã–µ –ø—Ä–µ–ø–∞—Ä–∞—Ç—ã** ‚Üí –∑–∞–º–µ–¥–ª–µ–Ω–∏–µ –∞–±—Å–æ—Ä–±—Ü–∏–∏ (–≥–∞—Å—Ç—Ä–æ–ø–∞—Ä–µ–∑) ‚Äî –ø—Ä–∏–Ω–∏–º–∞—Ç—å –∑–∞ 30 –º–∏–Ω –¥–æ –µ–¥—ã (–¥–ª—è –æ—Ä–∞–ª—å–Ω–æ–π —Ñ–æ—Ä–º—ã)
- **–°–µ–º–∞–≥–ª—É—Ç–∏–¥ + –≤–∞—Ä—Ñ–∞—Ä–∏–Ω** ‚Üí –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ –ú–ù–û (–∏–∑–º–µ–Ω–µ–Ω–∏–µ –∞–±—Å–æ—Ä–±—Ü–∏–∏)

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** –ª–∏—á–Ω—ã–π/—Å–µ–º–µ–π–Ω—ã–π –∞–Ω–∞–º–Ω–µ–∑ –º–µ–¥—É–ª–ª—è—Ä–Ω–æ–≥–æ —Ä–∞–∫–∞ —â–∏—Ç–æ–≤–∏–¥–Ω–æ–π –∂–µ–ª–µ–∑—ã, –ú–≠–ù 2 —Ç–∏–ø–∞
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** –ø–∞–Ω–∫—Ä–µ–∞—Ç–∏—Ç –≤ –∞–Ω–∞–º–Ω–µ–∑–µ, —Ç—è–∂—ë–ª–∞—è –≥–∞—Å—Ç—Ä–æ–ø–∞—Ä–µ–∑, –±–µ—Ä–µ–º–µ–Ω–Ω–æ—Å—Ç—å (–∫–∞—Ç–µ–≥–æ—Ä–∏—è D –≤ –ê–≤—Å—Ç—Ä–∞–ª–∏–∏)
- **FDA Black Box Warning:** C-–∫–ª–µ—Ç–æ—á–Ω—ã–µ –æ–ø—É—Ö–æ–ª–∏ —â–∏—Ç–æ–≤–∏–¥–Ω–æ–π –∂–µ–ª–µ–∑—ã —É –≥—Ä—ã–∑—É–Ω–æ–≤

### Practical Notes
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ (Ozempic, –¥–∏–∞–±–µ—Ç):** 0.25 –º–≥/–Ω–µ–¥ √ó 4 –Ω–µ–¥ ‚Üí 0.5 –º–≥/–Ω–µ–¥ √ó 4 –Ω–µ–¥ ‚Üí 1 –º–≥/–Ω–µ–¥
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ (Wegovy, –æ–∂–∏—Ä–µ–Ω–∏–µ):** —Ç–∏—Ç—Ä–∞—Ü–∏—è –¥–æ 2.4 –º–≥/–Ω–µ–¥ –∑–∞ 16‚Äì20 –Ω–µ–¥–µ–ª—å
- **–û—Ä–∞–ª—å–Ω–∞—è —Ñ–æ—Ä–º–∞ (Rybelsus):** 3 –º–≥ ‚Üí 7 –º–≥ ‚Üí 14 –º–≥, –Ω–∞—Ç–æ—â–∞–∫ —Å ‚â§120 –º–ª –≤–æ–¥—ã, –∑–∞ 30 –º–∏–Ω –¥–æ –µ–¥—ã
- –ì–ò –ø–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã (—Ç–æ—à–Ω–æ—Ç–∞, —Ä–≤–æ—Ç–∞) ‚Äî –Ω–∞–∏–±–æ–ª–µ–µ —á–∞—Å—Ç—ã–µ, –æ–±—ã—á–Ω–æ —É–º–µ–Ω—å—à–∞—é—Ç—Å—è –∑–∞ 4‚Äì8 –Ω–µ–¥–µ–ª—å
- –ì–∞—Å—Ç—Ä–æ–ø–∞—Ä–µ–∑ ‚Äî –æ–ø–∏—Å–∞–Ω —É 0.1% –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ (52% –ø–æ–≤—ã—à–µ–Ω–Ω—ã–π —Ä–∏—Å–∫ vs –±–µ–∑ GLP-1)
- –û–¥–æ–±—Ä–µ–Ω –≤ 2025 –¥–ª—è MASH (—Å—Ç–µ–∞—Ç–æ–≥–µ–ø–∞—Ç–∏—Ç)

---

## 4. –¢–∏—Ä–∑–µ–ø–∞—Ç–∏–¥ (Tirzepatide / Mounjaro / Zepbound)

### Mechanism of Action
- **–î–≤–æ–π–Ω–æ–π –∞–≥–æ–Ω–∏—Å—Ç GIP/GLP-1 —Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤** ‚Äî –ø–µ—Ä–≤—ã–π –≤ –∫–ª–∞—Å—Å–µ
- –ê–Ω–∞–ª–æ–≥ –≥–∞—Å—Ç—Ä–æ–∏–Ω–≥–∏–±–∏—Ç–æ—Ä–Ω–æ–≥–æ –ø–æ–ª–∏–ø–µ–ø—Ç–∏–¥–∞ (GIP) —Å –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç—å—é –Ω–∞ GLP-1 —Ä–µ—Ü–µ–ø—Ç–æ—Ä–µ
- –ë–æ–ª—å—à–µ–µ —Å—Ä–æ–¥—Å—Ç–≤–æ –∫ GIP-—Ä–µ—Ü–µ–ø—Ç–æ—Ä–∞–º, —á–µ–º –∫ GLP-1
- **Biased agonism** –Ω–∞ GLP-1R: –ø—Ä–µ–¥–ø–æ—á—Ç–µ–Ω–∏–µ —Ü–ê–ú–§-—Å–∏–≥–Ω–∞–ª–∏–∑–∞—Ü–∏–∏ –Ω–∞–¥ Œ≤-–∞—Ä—Ä–µ—Å—Ç–∏–Ω–æ–≤—ã–º –ø—É—Ç—ë–º ‚Üí —É—Å–∏–ª–µ–Ω–Ω–∞—è —Å–µ–∫—Ä–µ—Ü–∏—è –∏–Ω—Å—É–ª–∏–Ω–∞
- –ü–æ–≤—ã—à–∞–µ—Ç –∞–¥–∏–ø–æ–Ω–µ–∫—Ç–∏–Ω –¥–æ 26% –æ—Ç –∏—Å—Ö–æ–¥–Ω–æ–≥–æ
- –°–Ω–∏–∂–∞–µ—Ç –∏–Ω—Å—É–ª–∏–Ω–æ—Ä–µ–∑–∏—Å—Ç–µ–Ω—Ç–Ω–æ—Å—Ç—å (HOMA2-IR ~8%)
- –ü–æ–≤—ã—à–∞–µ—Ç IGFBP1 –∏ IGFBP2 ‚Üí —É–ª—É—á—à–µ–Ω–∏–µ —á—É–≤—Å—Ç–≤–∏—Ç–µ–ª—å–Ω–æ—Å—Ç–∏ –∫ –∏–Ω—Å—É–ª–∏–Ω—É
- –õ–∏–ø–∏–¥–Ω–∞—è –º–æ–¥–∏—Ñ–∏–∫–∞—Ü–∏—è (C20 –∂–∏—Ä–Ω–∞—è –¥–∏–∫–∏—Å–ª–æ—Ç–∞) ‚Üí —Å–≤—è–∑—å —Å –∞–ª—å–±—É–º–∏–Ω–æ–º ‚Üí T¬Ω **5 –¥–Ω–µ–π**
- –ë–∏–æ–¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å: 80% –ø/–∫

### Key Clinical Studies
- **SURPASS trial program (diabetes)**
  - SURPASS-2 (NCT03987919): —Å–Ω–∏–∂–µ–Ω–∏–µ HbA1c –Ω–∞ 2.01‚Äì2.30% (vs —Å–µ–º–∞–≥–ª—É—Ç–∏–¥ 1.86%)
  - –ü—Ä–µ–≤–æ—Å—Ö–æ–¥—Å—Ç–≤–æ –Ω–∞–¥ —Å–µ–º–∞–≥–ª—É—Ç–∏–¥–æ–º –ø–æ —Å–Ω–∏–∂–µ–Ω–∏—é HbA1c –∏ –º–∞—Å—Å—ã —Ç–µ–ª–∞
- **SURMOUNT trial program (obesity)**
  - SURMOUNT-1: —Å–Ω–∏–∂–µ–Ω–∏–µ –≤–µ—Å–∞ –¥–æ 22.5% –ø—Ä–∏ 15 –º–≥ –∑–∞ 72 –Ω–µ–¥–µ–ª–∏
  - –ù–∞–∏–±–æ–ª—å—à–µ–µ —Å–Ω–∏–∂–µ–Ω–∏–µ –≤–µ—Å–∞ —Å—Ä–µ–¥–∏ –≤—Å–µ—Ö –æ–¥–æ–±—Ä–µ–Ω–Ω—ã—Ö –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤
- –û–¥–æ–±—Ä–µ–Ω –¥–ª—è –û–°–ê (–æ–±—Å—Ç—Ä—É–∫—Ç–∏–≤–Ω–æ–µ –∞–ø–Ω–æ—ç —Å–Ω–∞) –ø—Ä–∏ –æ–∂–∏—Ä–µ–Ω–∏–∏ (–¥–µ–∫–∞–±—Ä—å 2024)

### Bloodwork Markers to Monitor
- **HbA1c / –≥–ª—é–∫–æ–∑–∞ –Ω–∞—Ç–æ—â–∞–∫** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–ê–º–∏–ª–∞–∑–∞ / –ª–∏–ø–∞–∑–∞** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–§—É–Ω–∫—Ü–∏—è –ø–æ—á–µ–∫** ‚Äî –∫–∞–∂–¥—ã–µ 3‚Äì6 –º–µ—Å—è—Ü–µ–≤
- **–ü–µ—á—ë–Ω–æ—á–Ω—ã–µ —Ñ–µ—Ä–º–µ–Ω—Ç—ã** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–¢–∏—Ä–µ–æ–∏–¥–Ω—ã–µ –º–∞—Ä–∫—ë—Ä—ã (–∫–∞–ª—å—Ü–∏—Ç–æ–Ω–∏–Ω)** ‚Äî –∫–∞–∂–¥—ã–µ 6 –º–µ—Å—è—Ü–µ–≤
- **–õ–∏–ø–∏–¥–Ω—ã–π –ø—Ä–æ—Ñ–∏–ª—å** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞ (–∑–Ω–∞—á–∏—Ç–µ–ª—å–Ω–æ–µ —É–ª—É—á—à–µ–Ω–∏–µ)
- **–ê–¥–∏–ø–æ–Ω–µ–∫—Ç–∏–Ω** ‚Äî –æ–ø—Ü–∏–æ–Ω–∞–ª—å–Ω–æ (–º–∞—Ä–∫—ë—Ä —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏)

### Drug Interactions
- **–¢–∏—Ä–∑–µ–ø–∞—Ç–∏–¥ + –∏–Ω—Å—É–ª–∏–Ω / —Å—É–ª—å—Ñ–æ–Ω–∏–ª–º–æ—á–µ–≤–∏–Ω–∞** ‚Üí –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—è (—Å–Ω–∏–∂–∞—Ç—å –¥–æ–∑—É)
- **–¢–∏—Ä–∑–µ–ø–∞—Ç–∏–¥ + –ø–µ—Ä–æ—Ä–∞–ª—å–Ω—ã–µ –ø—Ä–µ–ø–∞—Ä–∞—Ç—ã** ‚Üí –∑–∞–º–µ–¥–ª–µ–Ω–∏–µ –∞–±—Å–æ—Ä–±—Ü–∏–∏
- **–¢–∏—Ä–∑–µ–ø–∞—Ç–∏–¥ + –æ—Ä–∞–ª—å–Ω—ã–µ –∫–æ–Ω—Ç—Ä–∞—Ü–µ–ø—Ç–∏–≤—ã** ‚Üí —Å–Ω–∏–∂–µ–Ω–∏–µ —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ (–∑–∞–º–µ–¥–ª–µ–Ω–∏–µ –∞–±—Å–æ—Ä–±—Ü–∏–∏)
- –ü—Ä–æ—Ñ–∏–ª—å –≤–∑–∞–∏–º–æ–¥–µ–π—Å—Ç–≤–∏–π –∞–Ω–∞–ª–æ–≥–∏—á–µ–Ω –¥—Ä—É–≥–∏–º GLP-1 RA

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** –º–µ–¥—É–ª–ª—è—Ä–Ω—ã–π —Ä–∞–∫ —â–∏—Ç–æ–≤–∏–¥–Ω–æ–π –∂–µ–ª–µ–∑—ã (–ª–∏—á–Ω—ã–π/—Å–µ–º–µ–π–Ω—ã–π), –ú–≠–ù 2 —Ç–∏–ø–∞
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** –ø–∞–Ω–∫—Ä–µ–∞—Ç–∏—Ç –≤ –∞–Ω–∞–º–Ω–µ–∑–µ, —Ç—è–∂—ë–ª—ã–π –≥–∞—Å—Ç—Ä–æ–ø–∞—Ä–µ–∑, –±–µ—Ä–µ–º–µ–Ω–Ω–æ—Å—Ç—å (–∫–∞—Ç–µ–≥–æ—Ä–∏—è D)

### Practical Notes
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ:** 2.5 –º–≥/–Ω–µ–¥ √ó 4 –Ω–µ–¥ ‚Üí 5 –º–≥ ‚Üí 7.5 –º–≥ ‚Üí 10 –º–≥ ‚Üí 12.5 –º–≥ ‚Üí 15 –º–≥ (—Ç–∏—Ç—Ä–∞—Ü–∏—è –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏)
- –¢–æ–ª—å–∫–æ –ø/–∫ –∏–Ω—ä–µ–∫—Ü–∏—è, 1 —Ä–∞–∑ –≤ –Ω–µ–¥–µ–ª—é
- –ü—Ä–æ—Ü–µ–Ω—Ç –ø—Ä–µ–∫—Ä–∞—â–µ–Ω–∏—è –ª–µ—á–µ–Ω–∏—è —Ä–∞—Å—Ç—ë—Ç —Å –¥–æ–∑–æ–π: 5.1% (5 –º–≥) vs 25% (15 –º–≥) –∏–∑-–∑–∞ –ì–ò –ø–æ–±–æ—á–Ω—ã—Ö —ç—Ñ—Ñ–µ–∫—Ç–æ–≤
- **–ü—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–æ –Ω–∞–¥ —Å–µ–º–∞–≥–ª—É—Ç–∏–¥–æ–º:** –¥–≤–æ–π–Ω–æ–π –º–µ—Ö–∞–Ω–∏–∑–º ‚Üí –±–æ–ª—å—à–µ —Å–Ω–∏–∂–µ–Ω–∏–µ –≤–µ—Å–∞ –∏ HbA1c
- –°–∏—Å—Ç–µ–º–∞—Ç–∏—á–µ—Å–∫–∏–π –æ–±–∑–æ—Ä 2024: —Ö–æ—Ä–æ—à–∞—è –ø–µ—Ä–µ–Ω–æ—Å–∏–º–æ—Å—Ç—å, –ù–ï –∞—Å—Å–æ—Ü–∏–∏—Ä–æ–≤–∞–Ω —Å –ø–∞–Ω–∫—Ä–µ–∞—Ç–∏—Ç–æ–º
- UK MHRA (2026): –ø—Ä–µ–¥—É–ø—Ä–µ–∂–¥–µ–Ω–∏–µ –æ –º–∞–ª–æ–º —Ä–∏—Å–∫–µ —Ç—è–∂—ë–ª–æ–≥–æ –æ—Å—Ç—Ä–æ–≥–æ –ø–∞–Ω–∫—Ä–µ–∞—Ç–∏—Ç–∞

---

## 5. –≠—Ñ–µ–¥—Ä–∏–Ω / ECA-—Å—Ç–µ–∫ (Ephedrine / ECA Stack)

### Mechanism of Action
- **–ù–µ–ø—Ä—è–º–æ–π —Å–∏–º–ø–∞—Ç–æ–º–∏–º–µ—Ç–∏–∫** ‚Äî –∏–Ω–¥—É—Ü–∏—Ä—É–µ—Ç –≤—ã—Å–≤–æ–±–æ–∂–¥–µ–Ω–∏–µ –Ω–æ—Ä–∞–¥—Ä–µ–Ω–∞–ª–∏–Ω–∞ –∏–∑ –Ω–µ—Ä–≤–Ω—ã—Ö –æ–∫–æ–Ω—á–∞–Ω–∏–π
- –ù–µ–ø—Ä—è–º–∞—è –∞–∫—Ç–∏–≤–∞—Ü–∏—è Œ±- –∏ Œ≤-–∞–¥—Ä–µ–Ω–æ—Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤
- –°—Ç—Ä—É–∫—Ç—É—Ä–Ω–æ ‚Äî **–∑–∞–º–µ—â—ë–Ω–Ω—ã–π –∞–º—Ñ–µ—Ç–∞–º–∏–Ω** ((1R,2S)-Œ≤-–≥–∏–¥—Ä–æ–∫—Å–∏-N-–º–µ—Ç–∏–ª–∞–º—Ñ–µ—Ç–∞–º–∏–Ω)
- –°—Ç–∏–º—É–ª–∏—Ä—É–µ—Ç —Ç–µ—Ä–º–æ–≥–µ–Ω–µ–∑ (–ø—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–µ–Ω–Ω–æ –≤ —Å–∫–µ–ª–µ—Ç–Ω—ã—Ö –º—ã—à—Ü–∞—Ö)
- –ó–∞–º–µ–¥–ª—è–µ—Ç –æ–ø–æ—Ä–æ–∂–Ω–µ–Ω–∏–µ –∂–µ–ª—É–¥–∫–∞ ‚Üí —Å–Ω–∏–∂–µ–Ω–∏–µ –∞–ø–ø–µ—Ç–∏—Ç–∞
- –í—ã—Å–≤–æ–±–æ–∂–¥–µ–Ω–∏–µ –º–æ–Ω–æ–∞–º–∏–Ω–æ–≤: NE (EC50 43‚Äì72 nM), DA (EC50 236‚Äì1350 nM), 5-HT (>10000 nM)
- –ë–∏–æ–¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å: 88%, T¬Ω: 6 —á–∞—Å–æ–≤, –≤ –æ—Å–Ω–æ–≤–Ω–æ–º –≤—ã–≤–æ–¥–∏—Ç—Å—è –±–µ–∑ –º–µ—Ç–∞–±–æ–ª–∏–∑–º–∞ (60% —Å –º–æ—á–æ–π)
- **ECA —Å—Ç–µ–∫:** –≠—Ñ–µ–¥—Ä–∏–Ω + –ö–æ—Ñ–µ–∏–Ω + –ê—Å–ø–∏—Ä–∏–Ω ‚Äî —Å–∏–Ω–µ—Ä–≥–∏—á–µ—Å–∫–∏–π —ç—Ñ—Ñ–µ–∫—Ç

### Key Clinical Studies
- **–°–∏—Å—Ç–µ–º–∞—Ç–∏—á–µ—Å–∫–∏–π –æ–±–∑–æ—Ä 2021** (–∏–∑ Wikipedia)
  - Design: SR, doses 60‚Äì150 mg, ¬±caffeine, 4‚Äì24 weeks
  - Key finding: –°–Ω–∏–∂–µ–Ω–∏–µ –≤–µ—Å–∞ –Ω–∞ 2 –∫–≥ –±–æ–ª—å—à–µ —á–µ–º –ø–ª–∞—Ü–µ–±–æ, –ø–æ–≤—ã—à–µ–Ω–∏–µ –ß–°–°, —Å–Ω–∏–∂–µ–Ω–∏–µ –õ–ü–ù–ü, –ø–æ–≤—ã—à–µ–Ω–∏–µ –õ–ü–í–ü
  - Relevance: –£–º–µ—Ä–µ–Ω–Ω—ã–π, –Ω–æ –∑–Ω–∞—á–∏–º—ã–π —ç—Ñ—Ñ–µ–∫—Ç –Ω–∞ –∂–∏—Ä–æ—Å–∂–∏–≥–∞–Ω–∏–µ
  - Relevance: –ù–µ—Ç —Å—Ç–∞—Ç–∏—Å—Ç–∏—á–µ—Å–∫–∏ –∑–Ω–∞—á–∏–º–æ–≥–æ –ø–æ–≤—ã—à–µ–Ω–∏—è –ê–î

### Bloodwork Markers to Monitor
- **–ê–î** ‚Äî –ö–†–ò–¢–ò–ß–ù–û, –∫–∞–∂–¥–æ–µ –ø—Ä–∏–º–µ–Ω–µ–Ω–∏–µ (–≥–∏–ø–µ—Ä—Ç–µ–Ω–∑–∏—è)
- **–ß–°–° / –≠–ö–ì** ‚Äî —Ä–µ–≥—É–ª—è—Ä–Ω–æ (—Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è, –∞—Ä–∏—Ç–º–∏–∏)
- **–≠–ª–µ–∫—Ç—Ä–æ–ª–∏—Ç—ã (K+, Na+)** ‚Äî –∫–∞–∂–¥—ã–µ 2 –Ω–µ–¥–µ–ª–∏
- **–ì–ª—é–∫–æ–∑–∞** ‚Äî –º–æ–∂–µ—Ç –≤—ã–∑–≤–∞—Ç—å –≥–∏–ø–µ—Ä–≥–ª–∏–∫–µ–º–∏—é
- **–§—É–Ω–∫—Ü–∏—è –ø–µ—á–µ–Ω–∏** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏
- **–§—É–Ω–∫—Ü–∏—è –ø–æ—á–µ–∫** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏ (–≤–∞–∑–æ–∫–æ–Ω—Å—Ç—Ä–∏–∫—Ü–∏—è –ø–æ—á–µ—á–Ω—ã—Ö –∞—Ä—Ç–µ—Ä–∏–π)

### Drug Interactions
- ‚ö†Ô∏è **–≠—Ñ–µ–¥—Ä–∏–Ω + –ò–ú–ê–û (—Ñ–µ–Ω–µ–ª–∑–∏–Ω, —Ç—Ä–∞–Ω–∏–ª—Ü–∏–ø—Ä–æ–º–∏–Ω)** ‚Üí –ì–ò–ü–ï–†–¢–û–ù–ò–ß–ï–°–ö–ò–ô –ö–†–ò–ó ‚Äî –ü–†–û–¢–ò–í–û–ü–û–ö–ê–ó–ê–ù–û! (14 –¥–Ω–µ–π –º–∏–Ω–∏–º—É–º)
- ‚ö†Ô∏è **–≠—Ñ–µ–¥—Ä–∏–Ω + NDRI (–±—É–ø—Ä–æ–ø–∏–æ–Ω)** ‚Üí —á—Ä–µ–∑–º–µ—Ä–Ω—ã–π NE, –ø–æ–≤—ã—à–µ–Ω–Ω—ã–µ –ø–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã
- ‚ö†Ô∏è **–≠—Ñ–µ–¥—Ä–∏–Ω + –≥–∞–ª–æ–≥–µ–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ –∞–Ω–µ—Å—Ç–µ—Ç–∏–∫–∏ (–≥–∞–ª–æ—Ç–∞–Ω)** ‚Üí —Ç–∞—Ö–∏–∞—Ä–∏—Ç–º–∏–∏, —Ñ–∏–±—Ä–∏–ª–ª—è—Ü–∏—è
- ‚ö†Ô∏è **–≠—Ñ–µ–¥—Ä–∏–Ω + –∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª** ‚Üí –∞–¥–¥–∏—Ç–∏–≤–Ω–∞—è Œ≤-—Å—Ç–∏–º—É–ª—è—Ü–∏—è, –ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô —Ä–∏—Å–∫
- ‚ö†Ô∏è **–≠—Ñ–µ–¥—Ä–∏–Ω + T3** ‚Üí –∞–¥–¥–∏—Ç–∏–≤–Ω–∞—è –∫–∞—Ä–¥–∏–æ—Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å (Black Box Warning –æ—Ç FDA)
- **–≠—Ñ–µ–¥—Ä–∏–Ω + –∫–æ—Ñ–µ–∏–Ω** ‚Üí —Å–∏–Ω–µ—Ä–≥–∏—á–µ—Å–∫–∏–π —Ç–µ—Ä–º–æ–≥–µ–Ω–µ–∑ (–æ—Å–Ω–æ–≤–∞ ECA —Å—Ç–µ–∫–∞)
- **–≠—Ñ–µ–¥—Ä–∏–Ω + –∞—Å–ø–∏—Ä–∏–Ω** ‚Üí –ø–æ–¥–∞–≤–ª–µ–Ω–∏–µ PGE2 ‚Üí –ø—Ä–æ–ª–æ–Ω–≥–∏—Ä–æ–≤–∞–Ω–∏–µ –¥–µ–π—Å—Ç–≤–∏—è —ç—Ñ–µ–¥—Ä–∏–Ω–∞

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** –∑–∞–∫—Ä—ã—Ç–æ—É–≥–æ–ª—å–Ω–∞—è –≥–ª–∞—É–∫–æ–º–∞, —Ñ–µ–æ—Ö—Ä–æ–º–æ—Ü–∏—Ç–æ–º–∞, –ò–ì–°–° (—Å—É–±–∞–æ—Ä—Ç–∞–ª—å–Ω—ã–π —Å—Ç–µ–Ω–æ–∑), –ø—Ä–∏—ë–º –ò–ú–ê–û, —Ç–∞—Ö–∏–∞—Ä–∏—Ç–º–∏–∏, —Ñ–∏–±—Ä–∏–ª–ª—è—Ü–∏—è
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** –≥–∏–ø–µ—Ä—Ç–æ–Ω–∏—è, –≥–∏–ø–µ—Ä—Ç–∏—Ä–µ–æ–∑, –∞–¥–µ–Ω–æ–º–∞ –ø—Ä–æ—Å—Ç–∞—Ç—ã, —Å–∞—Ö–∞—Ä–Ω—ã–π –¥–∏–∞–±–µ—Ç, –°–°–ó, –±–µ—Ä–µ–º–µ–Ω–Ω–æ—Å—Ç—å
- >18000 —Å–æ–æ–±—â–µ–Ω–∏–π –æ –ø–æ–±–æ—á–Ω—ã—Ö —ç—Ñ—Ñ–µ–∫—Ç–∞—Ö –≤ FDA –¥–æ 2004

### Practical Notes
- **ECA —Å—Ç–µ–∫ (–∫–ª–∞—Å—Å–∏—á–µ—Å–∫–∏–π):** –≠—Ñ–µ–¥—Ä–∏–Ω 25 –º–≥ + –ö–æ—Ñ–µ–∏–Ω 200 –º–≥ + –ê—Å–ø–∏—Ä–∏–Ω 81 –º–≥, 2‚Äì3 —Ä–∞–∑–∞/–¥–µ–Ω—å
- –ù–∞—á–∏–Ω–∞—Ç—å —Å 1 –¥–æ–∑—ã/–¥–µ–Ω—å, —Ç–∏—Ç—Ä–æ–≤–∞—Ç—å –¥–æ 3 –¥–æ–∑
- **–¢–∞—Ö–∏—Ñ–∏–ª–∞–∫—Å–∏—è** ‚Äî —Ä–∞–∑–≤–∏–≤–∞–µ—Ç—Å—è –ø—Ä–∏ –ø–æ–≤—Ç–æ—Ä–Ω–æ–º –≤/–≤ –≤–≤–µ–¥–µ–Ω–∏–∏ (–∏—Å—Ç–æ—â–µ–Ω–∏–µ –∫–∞—Ç–µ—Ö–æ–ª–∞–º–∏–Ω–æ–≤—ã—Ö –∑–∞–ø–∞—Å–æ–≤)
- –ö—É—Ä—Å: 4‚Äì8 –Ω–µ–¥–µ–ª—å —Å –ø–µ—Ä–µ—Ä—ã–≤–∞–º–∏
- –ó–∞–ø—Ä–µ—â—ë–Ω –∫–∞–∫ –ë–ê–î –≤ –°–®–ê (—Ä–∞–∑—Ä–µ—à—ë–Ω —Ç–æ–ª—å–∫–æ –ø–æ —Ä–µ—Ü–µ–ø—Ç—É –∏–ª–∏ –∫–∞–∫ —Ç—Ä–∞–¥–∏—Ü–∏–æ–Ω–Ω–∞—è –∫–∏—Ç–∞–π—Å–∫–∞—è –º–µ–¥–∏—Ü–∏–Ω–∞ ‚Äî –º–∞ —Ö—É–∞–Ω)
- –ó–∞–≤–∏—Å–∏–º–æ—Å—Ç—å: —Ñ–∏–∑–∏—á–µ—Å–∫–∞—è ‚Äî –Ω–∏–∑–∫–∞—è, –ø—Å–∏—Ö–æ–ª–æ–≥–∏—á–µ—Å–∫–∞—è ‚Äî —É–º–µ—Ä–µ–Ω–Ω–∞—è

---

## 6. –ô–æ—Ö–∏–º–±–∏–Ω (Yohimbine)

### Mechanism of Action
- **–°–µ–ª–µ–∫—Ç–∏–≤–Ω—ã–π –∞–Ω—Ç–∞–≥–æ–Ω–∏—Å—Ç Œ±2-–∞–¥—Ä–µ–Ω–æ—Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤** (Ki = 1.05 nM –¥–ª—è Œ±2A, 1.19 nM –¥–ª—è Œ±2B/C)
- –ë–ª–æ–∫–∞–¥–∞ –ø—Ä–µ—Å–∏–Ω–∞–ø—Ç–∏—á–µ—Å–∫–∏—Ö Œ±2-—Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤ ‚Üí —É—Å–∏–ª–µ–Ω–∏–µ –≤—ã—Å–≤–æ–±–æ–∂–¥–µ–Ω–∏—è –ù–ê –∏ NO
- –°–æ–æ—Ç–Ω–æ—à–µ–Ω–∏–µ Œ±2/Œ±1 —Å–µ–ª–µ–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏: 40:1
- –ï–¥–∏–Ω—Å—Ç–≤–µ–Ω–Ω—ã–π Œ±2-–∞–Ω—Ç–∞–≥–æ–Ω–∏—Å—Ç –ë–ï–ó –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ –Ω–∞ –∏–º–∏–¥–∞–∑–æ–ª–∏–Ω–æ–≤—ã—Ö —Ä–µ—Ü–µ–ø—Ç–æ—Ä–∞—Ö
- –¢–∞–∫–∂–µ —Å–≤—è–∑—ã–≤–∞–µ—Ç—Å—è —Å: 5-HT1B (Ki 19.9), 5-HT2B (Ki 43‚Äì144), D2 (Ki 339)
- –£—Å–∏–ª–µ–Ω–∏–µ –ª–∏–ø–æ–ª–∏–∑–∞ –≤ "—É–ø—Ä—è–º—ã—Ö" –∂–∏—Ä–æ–≤—ã—Ö –¥–µ–ø–æ (–±–æ–≥–∞—Ç—ã—Ö Œ±2-—Ä–µ—Ü–µ–ø—Ç–æ—Ä–∞–º–∏): –±—ë–¥—Ä–∞, –∂–∏–≤–æ—Ç, —è–≥–æ–¥–∏—Ü—ã
- –ë–∏–æ–¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å: 7‚Äì86% (—Å—Ä–µ–¥–Ω–µ–µ 33%) ‚Äî –û–ì–†–û–ú–ù–ê–Ø –≤–∞—Ä–∏–∞–±–µ–ª—å–Ω–æ—Å—Ç—å!
- T¬Ω: 0.25‚Äì2.5 —á–∞—Å–∞ (–æ—á–µ–Ω—å –∫–æ—Ä–æ—Ç–∫–∏–π)

### Key Clinical Studies
- **Cohen PA, 2015** (—Å—Å—ã–ª–∫–∞ –∏–∑ Wikipedia, PMID: verify)
  - Design: Analysis of OTC supplements
  - Key finding: –ö—Ä–∞–π–Ω–µ –≤–∞—Ä–∏–∞–±–µ–ª—å–Ω–æ–µ —Å–æ–¥–µ—Ä–∂–∞–Ω–∏–µ –π–æ—Ö–∏–º–±–∏–Ω–∞ –≤ –¥–æ–±–∞–≤–∫–∞—Ö, –Ω–µ–∫–æ—Ç–æ—Ä—ã–µ –ø—Ä–æ–¥—É–∫—Ç—ã –Ω–µ —Å–æ–¥–µ—Ä–∂–∞—Ç –µ–≥–æ –≤–æ–æ–±—â–µ
  - Relevance: –ü—Ä–æ–±–ª–µ–º–∞ –∫–∞—á–µ—Å—Ç–≤–∞ –¥–æ–±–∞–≤–æ–∫ ‚Äî –ë–ê–î—ã –Ω–µ–Ω–∞–¥—ë–∂–Ω—ã
- **EFSA Panel, 2013** (–∏–∑ Wikipedia)
  - Design: Safety assessment
  - Key finding: –ù–µ–≤–æ–∑–º–æ–∂–Ω–æ —É—Å—Ç–∞–Ω–æ–≤–∏—Ç—å –±–µ–∑–æ–ø–∞—Å–Ω—ã–π —É—Ä–æ–≤–µ–Ω—å –∏–∑-–∑–∞ –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω—ã—Ö –¥–∞–Ω–Ω—ã—Ö –æ —Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç–∏
  - Relevance: –†–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã–µ –æ—Ä–≥–∞–Ω—ã —Å—á–∏—Ç–∞—é—Ç –¥–æ–±–∞–≤–∫—É –Ω–µ–±–µ–∑–æ–ø–∞—Å–Ω–æ–π
- **Tennessee Poison Center Warning, 2022**
  - Key finding: –ü–æ—Ç–µ–Ω—Ü–∏–∞–ª—å–Ω–æ —Ñ–∞—Ç–∞–ª—å–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã OTC –¥–æ–±–∞–≤–æ–∫ –π–æ—Ö–∏–º–±–µ –∏–∑-–∑–∞ –Ω–µ—Ä–µ–≥—É–ª–∏—Ä—É–µ–º–æ–≥–æ —Å–æ–¥–µ—Ä–∂–∞–Ω–∏—è

### Bloodwork Markers to Monitor
- **–ê–î** ‚Äî –∫–∞–∂–¥–æ–µ –ø—Ä–∏–º–µ–Ω–µ–Ω–∏–µ (–≥–∏–ø–µ—Ä—Ç–µ–Ω–∑–∏—è –ø—Ä–∏ –≤—ã—Å–æ–∫–∏—Ö –¥–æ–∑–∞—Ö)
- **–ß–°–° / –≠–ö–ì** ‚Äî —Ä–µ–≥—É–ª—è—Ä–Ω–æ (—Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è)
- **–ì–ª—é–∫–æ–∑–∞** ‚Äî –º–æ–∂–µ—Ç –ø–æ–≤—ã—à–∞—Ç—å—Å—è
- **–§—É–Ω–∫—Ü–∏—è –ø–µ—á–µ–Ω–∏** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏
- **–ö–æ—Ä—Ç–∏–∑–æ–ª** ‚Äî –π–æ—Ö–∏–º–±–∏–Ω –ø–æ–≤—ã—à–∞–µ—Ç –∫–æ—Ä—Ç–∏–∑–æ–ª

### Drug Interactions
- ‚ö†Ô∏è **–ô–æ—Ö–∏–º–±–∏–Ω + –∞–Ω—Ç–∏–≥–∏–ø–µ—Ä—Ç–µ–Ω–∑–∏–≤–Ω—ã–µ** ‚Üí —á—Ä–µ–∑–º–µ—Ä–Ω–∞—è –≥–∏–ø–æ—Ç–µ–Ω–∑–∏—è –ò–õ–ò –Ω–µ–ø—Ä–µ–¥—Å–∫–∞–∑—É–µ–º—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã
- ‚ö†Ô∏è **–ô–æ—Ö–∏–º–±–∏–Ω + NRI (–∏–º–∏–ø—Ä–∞–º–∏–Ω)** ‚Üí –ø–∞–Ω–∏–∫–∞, –≤—ã—Ä–∞–∂–µ–Ω–Ω–∞—è —Ç—Ä–µ–≤–æ–∂–Ω–æ—Å—Ç—å
- ‚ö†Ô∏è **–ô–æ—Ö–∏–º–±–∏–Ω + –ò–ú–ê–û** ‚Üí –≥–∏–ø–µ—Ä—Ç–æ–Ω–∏—á–µ—Å–∫–∏–π –∫—Ä–∏–∑
- ‚ö†Ô∏è **–ô–æ—Ö–∏–º–±–∏–Ω + —Å—Ç–∏–º—É–ª—è—Ç–æ—Ä—ã (–∫–æ—Ñ–µ–∏–Ω, —ç—Ñ–µ–¥—Ä–∏–Ω, –∫–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª)** ‚Üí –∞–¥–¥–∏—Ç–∏–≤–Ω–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è, —Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è
- **–ô–æ—Ö–∏–º–±–∏–Ω + –±–µ–Ω–∑–æ–¥–∏–∞–∑–µ–ø–∏–Ω—ã/–±–∞—Ä–±–∏—Ç—É—Ä–∞—Ç—ã** ‚Üí —Å–Ω–∏–∂–µ–Ω–∏–µ —Ç—Ä–µ–≤–æ–∂–Ω–æ—Å—Ç–∏ –æ—Ç –π–æ—Ö–∏–º–±–∏–Ω–∞
- **–ö–†–ò–¢–ò–ß–ù–û:** –æ–±—à–∏—Ä–Ω—ã–µ –≤–∑–∞–∏–º–æ–¥–µ–π—Å—Ç–≤–∏—è —Å —Ä–µ—Ü–µ–ø—Ç—É—Ä–Ω—ã–º–∏ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞–º–∏, –≤–∫–ª—é—á–∞—è –≥–∏–ø–æ—Ç–µ–Ω–∑–∏—é, –∞—Ä–∏—Ç–º–∏–∏, —Å–µ—Ä–¥–µ—á–Ω—É—é –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å, –°–ú–ï–†–¢–¨

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** —Å–µ—Ä–¥–µ—á–Ω–∞—è –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å, –∏—à–µ–º–∏—á–µ—Å–∫–∞—è –±–æ–ª–µ–∑–Ω—å —Å–µ—Ä–¥—Ü–∞, –ü–¢–°–† –∏ —Ç—Ä–µ–≤–æ–∂–Ω—ã–µ —Ä–∞—Å—Å—Ç—Ä–æ–π—Å—Ç–≤–∞, –ø–µ—á—ë–Ω–æ—á–Ω–∞—è/–ø–æ—á–µ—á–Ω–∞—è –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** –ø—Å–∏—Ö–∏–∞—Ç—Ä–∏—á–µ—Å–∫–∏–µ —Ä–∞—Å—Å—Ç—Ä–æ–π—Å—Ç–≤–∞ (–≤—ã—Ä–∞–∂–µ–Ω–Ω–∞—è —Ç—Ä–µ–≤–æ–∂–Ω–æ—Å—Ç—å ‚Äî –æ—Å–Ω–æ–≤–Ω–æ–π –ø–æ–±–æ—á–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç)
- –ó–∞–ø—Ä–µ—â—ë–Ω –≤–æ –º–Ω–æ–≥–∏—Ö —Å—Ç—Ä–∞–Ω–∞—Ö (–ö–∞–Ω–∞–¥–∞ ‚Äî —É–±—Ä–∞–Ω —Å —Ä—ã–Ω–∫–∞ 2019, –í–µ–ª–∏–∫–æ–±—Ä–∏—Ç–∞–Ω–∏—è ‚Äî –∑–∞–ø—Ä–µ—â—ë–Ω –∫–∞–∫ –ë–ê–î)

### Practical Notes
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ:** 2.5‚Äì20 –º–≥/–¥–µ–Ω—å, —Ä–∞–∑–¥–µ–ª–∏—Ç—å –Ω–∞ 2‚Äì3 –ø—Ä–∏—ë–º–∞
- –ü—Ä–∏–Ω–∏–º–∞—Ç—å –ù–ê–¢–û–©–ê–ö ‚Äî –µ–¥–∞ (–∏–Ω—Å—É–ª–∏–Ω) –ø–æ–ª–Ω–æ—Å—Ç—å—é –±–ª–æ–∫–∏—Ä—É–µ—Ç —ç—Ñ—Ñ–µ–∫—Ç (Œ±2-—Ä–µ—Ü–µ–ø—Ç–æ—Ä—ã)
- –ù–∞–∏–±–æ–ª–µ–µ —ç—Ñ—Ñ–µ–∫—Ç–∏–≤–µ–Ω –¥–ª—è "—É–ø—Ä—è–º–æ–≥–æ" –∂–∏—Ä–∞ –ø—Ä–∏ –Ω–∏–∑–∫–æ–º % –∂–∏—Ä–∞ (—É–∂–µ <15% —É –º—É–∂—á–∏–Ω)
- **–¢–û–õ–¨–ö–û —Ñ–∞—Ä–º-grade –π–æ—Ö–∏–º–±–∏–Ω HCl** ‚Äî –ù–ï –¥–æ–±–∞–≤–∫–∏ "yohimbe bark" (–Ω–µ–ø—Ä–µ–¥—Å–∫–∞–∑—É–µ–º—ã–π —Å–æ—Å—Ç–∞–≤)
- –ü—Å–∏—Ö–æ–∞–∫—Ç–∏–≤–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç: –≤—ã—Ä–∞–∂–µ–Ω–Ω–∞—è —Ç—Ä–µ–≤–æ–∂–Ω–æ—Å—Ç—å, –±–µ—Å–ø–æ–∫–æ–π—Å—Ç–≤–æ, —Ä–∞–∑–¥—Ä–∞–∂–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å ‚Äî "–∫—Ä–∞–π–Ω–µ –Ω–µ–ø—Ä–∏—è—Ç–µ–Ω"
- –ò—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è –≤ –≤–µ—Ç–µ—Ä–∏–Ω–∞—Ä–∏–∏ –¥–ª—è —Ä–µ–≤–µ—Ä—Å–∏—Ä–æ–≤–∞–Ω–∏—è –∫—Å–∏–ª–∞–∑–∏–Ω–∞

---

## –ò–ù–°–£–õ–ò–ù (INSULIN)

---

## 7. –ò–Ω—Å—É–ª–∏–Ω –õ–∏–∑–ø—Ä–æ / –•—É–º–∞–ª–æ–≥ (Insulin Lispro / Humalog)

### Mechanism of Action
- **–ë—ã—Å—Ç—Ä–æ–¥–µ–π—Å—Ç–≤—É—é—â–∏–π –∞–Ω–∞–ª–æ–≥ —á–µ–ª–æ–≤–µ—á–µ—Å–∫–æ–≥–æ –∏–Ω—Å—É–ª–∏–Ω–∞** ‚Äî –∏–Ω–≤–µ—Ä—Å–∏—è –æ—Å—Ç–∞—Ç–∫–æ–≤ –ª–∏–∑–∏–Ω–∞ –∏ –ø—Ä–æ–ª–∏–Ω–∞ –≤ –ø–æ–∑–∏—Ü–∏—è—Ö B28 –∏ B29
- –≠—Ç–∞ –∏–Ω–≤–µ—Ä—Å–∏—è –ø—Ä–µ–¥–æ—Ç–≤—Ä–∞—â–∞–µ—Ç –æ–±—Ä–∞–∑–æ–≤–∞–Ω–∏–µ –≥–µ–∫—Å–∞–º–µ—Ä–æ–≤ ‚Üí –±—ã—Å—Ç—Ä–∞—è –∞–±—Å–æ—Ä–±—Ü–∏—è –∏–∑ –ø–æ–¥–∫–æ–∂–Ω–æ–≥–æ –¥–µ–ø–æ
- –°–≤—è–∑—ã–≤–∞–µ—Ç—Å—è —Å –∏–Ω—Å—É–ª–∏–Ω–æ–≤—ã–º —Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–º (—Ç–∏—Ä–æ–∑–∏–Ω–∫–∏–Ω–∞–∑–∞) ‚Üí –∫–∞—Å–∫–∞–¥ —Ñ–æ—Å—Ñ–æ—Ä–∏–ª–∏—Ä–æ–≤–∞–Ω–∏—è
- **–û—Å–Ω–æ–≤–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã:**
  - –ê–∫—Ç–∏–≤–∞—Ü–∏—è GLUT4 —Ç—Ä–∞–Ω—Å–ø–æ—Ä—Ç—ë—Ä–æ–≤ ‚Üí –∑–∞—Ö–≤–∞—Ç –≥–ª—é–∫–æ–∑—ã –º—ã—à—Ü–∞–º–∏ –∏ –∂–∏—Ä–æ–≤–æ–π —Ç–∫–∞–Ω—å—é
  - –°—Ç–∏–º—É–ª—è—Ü–∏—è –≥–ª–∏–∫–æ–≥–µ–Ω–µ–∑–∞ (–ø–µ—á–µ–Ω—å, –º—ã—à—Ü—ã)
  - –°—Ç–∏–º—É–ª—è—Ü–∏—è –ª–∏–ø–æ–≥–µ–Ω–µ–∑–∞
  - –°—Ç–∏–º—É–ª—è—Ü–∏—è —Å–∏–Ω—Ç–µ–∑–∞ –±–µ–ª–∫–∞ (–∞–Ω–∞–±–æ–ª–∏—á–µ—Å–∫–∏–π —ç—Ñ—Ñ–µ–∫—Ç)
  - –ü–æ–¥–∞–≤–ª–µ–Ω–∏–µ –≥–ª—é–∫–æ–Ω–µ–æ–≥–µ–Ω–µ–∑–∞ –∏ –≥–ª–∏–∫–æ–≥–µ–Ω–æ–ª–∏–∑–∞
  - –ü–æ–¥–∞–≤–ª–µ–Ω–∏–µ –ª–∏–ø–æ–ª–∏–∑–∞ –∏ –ø—Ä–æ—Ç–µ–æ–ª–∏–∑–∞
- **–§–∞—Ä–º–∞–∫–æ–∫–∏–Ω–µ—Ç–∏–∫–∞:**
  - –ù–∞—á–∞–ª–æ –¥–µ–π—Å—Ç–≤–∏—è: **15 –º–∏–Ω—É—Ç**
  - –ü–∏–∫: **30‚Äì90 –º–∏–Ω—É—Ç**
  - –î–ª–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å: **3‚Äì5 —á–∞—Å–æ–≤**

### Key Clinical Studies
- **Anderson JH Jr et al., 1997** (PMID: 9203460)
  - Design: Multicenter RCT, N=1008, insulin lispro vs regular human insulin
  - Key finding: Lispro –æ–±–µ—Å–ø–µ—á–∏–ª –ª—É—á—à–∏–π –ø–æ—Å—Ç–ø—Ä–∞–Ω–¥–∏–∞–ª—å–Ω—ã–π –∫–æ–Ω—Ç—Ä–æ–ª—å –≥–ª—é–∫–æ–∑—ã, –º–µ–Ω—å—à–µ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–π
  - Relevance: –û–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ –¥–ª—è –∑–∞–º–µ–Ω—ã –æ–±—ã—á–Ω–æ–≥–æ –∏–Ω—Å—É–ª–∏–Ω–∞
- **Holleman F, Hoekstra JB, 1997** (PMID: 9185147)
  - Design: Review
  - Key finding: Lispro-–∏–Ω—Å—É–ª–∏–Ω: –ø—Ä–æ—Ñ–∏–ª—å –±—ã—Å—Ç—Ä–µ–µ —Ñ–∏–∑–∏–æ–ª–æ–≥–∏—á–µ—Å–∫–æ–≥–æ –∏–Ω—Å—É–ª–∏–Ω–∞, –ª—É—á—à–µ –∫–æ–Ω—Ç—Ä–æ–ª—å –ø–æ—Å–ª–µ –µ–¥—ã
  - Relevance: –§–∞—Ä–º–∞–∫–æ–ª–æ–≥–∏—á–µ—Å–∫–æ–µ –æ–±–æ—Å–Ω–æ–≤–∞–Ω–∏–µ
- **Plank J et al., 2005** (PMID: 15677784)
  - Design: Systematic review of rapid-acting insulin analogs
  - Key finding: –°–∫—Ä–æ–º–Ω–æ–µ —Å–Ω–∏–∂–µ–Ω–∏–µ HbA1c (~0.1%), –∑–Ω–∞—á–∏–º–æ–µ —Å–Ω–∏–∂–µ–Ω–∏–µ –ø–æ—Å—Ç–ø—Ä–∞–Ω–¥–∏–∞–ª—å–Ω–æ–π –≥–∏–ø–µ—Ä–≥–ª–∏–∫–µ–º–∏–∏ –∏ —Ç—è–∂—ë–ª—ã—Ö –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–π
  - Relevance: –ë–µ–∑–æ–ø–∞—Å–Ω–æ—Å—Ç—å –±—ã—Å—Ç—Ä–æ–¥–µ–π—Å—Ç–≤—É—é—â–∏—Ö –∞–Ω–∞–ª–æ–≥–æ–≤

### ‚ö†Ô∏è –ì–ò–ü–û–ì–õ–ò–ö–ï–ú–ò–Ø ‚Äî –ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô –†–ê–ó–î–ï–õ

**–ì–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—è ‚Äî –ì–õ–ê–í–ù–´–ô –ò –ü–û–¢–ï–ù–¶–ò–ê–õ–¨–ù–û –°–ú–ï–†–¢–ï–õ–¨–ù–´–ô —Ä–∏—Å–∫ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏—è –∏–Ω—Å—É–ª–∏–Ω–∞**

#### –°—Ç–µ–ø–µ–Ω–∏ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏:
| –£—Ä–æ–≤–µ–Ω—å | –ì–ª—é–∫–æ–∑–∞ | –°–∏–º–ø—Ç–æ–º—ã | –î–µ–π—Å—Ç–≤–∏—è |
|---------|---------|----------|----------|
| –õ—ë–≥–∫–∞—è | 3.0‚Äì3.9 –º–º–æ–ª—å/–ª | –¢—Ä–µ–º–æ—Ä, –ø–æ—Ç–ª–∏–≤–æ—Å—Ç—å, –≥–æ–ª–æ–¥, —Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è | 15‚Äì20 –≥ –±—ã—Å—Ç—Ä—ã—Ö —É–≥–ª–µ–≤–æ–¥–æ–≤ |
| –£–º–µ—Ä–µ–Ω–Ω–∞—è | 2.2‚Äì3.0 –º–º–æ–ª—å/–ª | –°–ø—É—Ç–∞–Ω–Ω–æ—Å—Ç—å, —Å–ª–∞–±–æ—Å—Ç—å, –Ω–∞—Ä—É—à–µ–Ω–∏–µ –∫–æ–æ—Ä–¥–∏–Ω–∞—Ü–∏–∏ | 30‚Äì40 –≥ —É–≥–ª–µ–≤–æ–¥–æ–≤, –ø–æ–º–æ—â—å |
| –¢—è–∂—ë–ª–∞—è | <2.2 –º–º–æ–ª—å/–ª | –ü–æ—Ç–µ—Ä—è —Å–æ–∑–Ω–∞–Ω–∏—è, —Å—É–¥–æ—Ä–æ–≥–∏, –ö–û–ú–ê | –ì–ª—é–∫–∞–≥–æ–Ω 1 –º–≥ –≤/–º, –≤—ã–∑–æ–≤ —Å–∫–æ—Ä–æ–π |
| **–°–ú–ï–†–¢–¨** | <1.0 –º–º–æ–ª—å/–ª | –ù–µ–æ–±—Ä–∞—Ç–∏–º–æ–µ –ø–æ–≤—Ä–µ–∂–¥–µ–Ω–∏–µ –º–æ–∑–≥–∞, –æ—Å—Ç–∞–Ω–æ–≤–∫–∞ —Å–µ—Ä–¥—Ü–∞ | ‚Äî |

#### –ü—Ä–∞–≤–∏–ª–æ 15-15:
1. –ü—Ä–∏–Ω—è—Ç—å 15 –≥ –±—ã—Å—Ç—Ä—ã—Ö —É–≥–ª–µ–≤–æ–¥–æ–≤ (—Å–æ–∫, –≥–ª—é–∫–æ–∑–∞, –º—ë–¥)
2. –ü–æ–¥–æ–∂–¥–∞—Ç—å 15 –º–∏–Ω—É—Ç
3. –ü–µ—Ä–µ–º–µ—Ä–∏—Ç—å –≥–ª—é–∫–æ–∑—É
4. –ü–æ–≤—Ç–æ—Ä–∏—Ç—å –µ—Å–ª–∏ –≤—Å—ë –µ—â—ë <4.0 –º–º–æ–ª—å/–ª

#### –û–ë–Ø–ó–ê–¢–ï–õ–¨–ù–´–ï –ø—Ä–∞–≤–∏–ª–∞ –±–µ–∑–æ–ø–∞—Å–Ω–æ—Å—Ç–∏ –ø—Ä–∏ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–∏ –∏–Ω—Å—É–ª–∏–Ω–∞:
1. ‚úÖ **–í–°–ï–ì–î–ê –∏–º–µ—Ç—å –ø—Ä–∏ —Å–µ–±–µ –±—ã—Å—Ç—Ä—ã–µ —É–≥–ª–µ–≤–æ–¥—ã** (–¥–µ–∫—Å—Ç—Ä–æ–∑–∞, —Å–æ–∫)
2. ‚úÖ **–í–°–ï–ì–î–ê –∏–º–µ—Ç—å –≥–ª—é–∫–∞–≥–æ–Ω** (—ç–∫—Å—Ç—Ä–µ–Ω–Ω—ã–π –Ω–∞–±–æ—Ä)
3. ‚úÖ **–ù–ò–ö–û–ì–î–ê –Ω–µ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞—Ç—å –≤ –æ–¥–∏–Ω–æ—á–µ—Å—Ç–≤–µ** ‚Äî —Ä—è–¥–æ–º –¥–æ–ª–∂–µ–Ω –±—ã—Ç—å —á–µ–ª–æ–≤–µ–∫, –∑–Ω–∞—é—â–∏–π —Å–∏–º–ø—Ç–æ–º—ã –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏
4. ‚úÖ **–í–°–ï–ì–î–ê –∏–º–µ—Ç—å –≥–ª—é–∫–æ–º–µ—Ç—Ä** ‚Äî –∏–∑–º–µ—Ä—è—Ç—å –¥–æ –∏ –∫–∞–∂–¥—ã–µ 15‚Äì30 –º–∏–Ω –ø–æ—Å–ª–µ –∏–Ω—ä–µ–∫—Ü–∏–∏
5. ‚úÖ **–ù–ò–ö–û–ì–î–ê –Ω–µ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞—Ç—å –ø–µ—Ä–µ–¥ —Å–Ω–æ–º** ‚Äî —Å–º–µ—Ä—Ç—å –≤–æ —Å–Ω–µ –æ—Ç –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏
6. ‚úÖ **–ù–ò–ö–û–ì–î–ê –Ω–µ –∏—Å–ø–æ–ª—å–∑–æ–≤–∞—Ç—å –ø–µ—Ä–µ–¥ —Ç—Ä–µ–Ω–∏—Ä–æ–≤–∫–æ–π** ‚Äî —Ñ–∏–∑–Ω–∞–≥—Ä—É–∑–∫–∞ —É—Å–∏–ª–∏–≤–∞–µ—Ç —ç—Ñ—Ñ–µ–∫—Ç
7. ‚úÖ **–¢–æ—á–Ω–∞—è –¥–æ–∑–∏—Ä–æ–≤–∫–∞** ‚Äî –∏–Ω—Å—É–ª–∏–Ω–æ–≤—ã–µ —à–ø—Ä–∏—Ü—ã –¢–û–õ–¨–ö–û

### Bloodwork Markers to Monitor
- **–ì–ª—é–∫–æ–∑–∞ –∫—Ä–æ–≤–∏** ‚Äî –ö–ê–ñ–î–û–ï –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ (–¥–æ, —á–µ—Ä–µ–∑ 30, 60, 90, 120 –º–∏–Ω)
- **HbA1c** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞ (–ø—Ä–∏ —Ä–µ–≥—É–ª—è—Ä–Ω–æ–º –∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–∏)
- **C-–ø–µ–ø—Ç–∏–¥** ‚Äî –∫–∞–∂–¥—ã–µ 3‚Äì6 –º–µ—Å—è—Ü–µ–≤ (–æ—Ü–µ–Ω–∫–∞ —Å–æ–±—Å—Ç–≤–µ–Ω–Ω–æ–π —Å–µ–∫—Ä–µ—Ü–∏–∏)
- **–ö–∞–ª–∏–π (K+)** ‚Äî –∫–∞–∂–¥—ã–µ 2 –Ω–µ–¥–µ–ª–∏ (–∏–Ω—Å—É–ª–∏–Ω –∑–∞–≥–æ–Ω—è–µ—Ç K+ –≤ –∫–ª–µ—Ç–∫–∏ ‚Üí –≥–∏–ø–æ–∫–∞–ª–∏–µ–º–∏—è)
- **–ú–∞–≥–Ω–∏–π** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏
- **–§—É–Ω–∫—Ü–∏—è –ø–µ—á–µ–Ω–∏ / –ø–æ—á–µ–∫** ‚Äî –∫–∞–∂–¥—ã–µ 4 –Ω–µ–¥–µ–ª–∏
- **–ú–∞—Å—Å–∞ —Ç–µ–ª–∞ / % –∂–∏—Ä–∞** ‚Äî –∏–Ω—Å—É–ª–∏–Ω ‚Üí –ª–∏–ø–æ–≥–µ–Ω–µ–∑

### Drug Interactions
- ‚ö†Ô∏è **–ò–Ω—Å—É–ª–∏–Ω + —Å—É–ª—å—Ñ–æ–Ω–∏–ª–º–æ—á–µ–≤–∏–Ω–∞ / –¥—Ä—É–≥–∏–µ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—á–µ—Å–∫–∏–µ** ‚Üí —É—Å–∏–ª–µ–Ω–∏–µ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏
- ‚ö†Ô∏è **–ò–Ω—Å—É–ª–∏–Ω + Œ≤-–±–ª–æ–∫–∞—Ç–æ—Ä—ã** ‚Üí –ú–ê–°–ö–ò–†–£–Æ–¢ —Å–∏–º–ø—Ç–æ–º—ã –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏ (—Ç—Ä–µ–º–æ—Ä, —Ç–∞—Ö–∏–∫–∞—Ä–¥–∏—è)
- ‚ö†Ô∏è **–ò–Ω—Å—É–ª–∏–Ω + –∞–ª–∫–æ–≥–æ–ª—å** ‚Üí —É—Å–∏–ª–µ–Ω–∏–µ –∏ –ø—Ä–æ–ª–æ–Ω–≥–∏—Ä–æ–≤–∞–Ω–∏–µ –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏–∏
- ‚ö†Ô∏è **–ò–Ω—Å—É–ª–∏–Ω + —Ç–∏–∞–∑–æ–ª–∏–¥–∏–Ω–¥–∏–æ–Ω—ã** ‚Üí –∑–∞–¥–µ—Ä–∂–∫–∞ –∂–∏–¥–∫–æ—Å—Ç–∏, —Å–µ—Ä–¥–µ—á–Ω–∞—è –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å
- **–ò–Ω—Å—É–ª–∏–Ω + T3/—Ç–∏—Ä–µ–æ–∏–¥–Ω—ã–µ –≥–æ—Ä–º–æ–Ω—ã** ‚Üí –∞–Ω—Ç–∞–≥–æ–Ω–∏–∑–º (T3 –ø–æ–≤—ã—à–∞–µ—Ç –≥–ª—é–∫–æ–∑—É)
- **–ò–Ω—Å—É–ª–∏–Ω + –ì–† (–≥–æ—Ä–º–æ–Ω —Ä–æ—Å—Ç–∞)** ‚Üí –∞–Ω—Ç–∞–≥–æ–Ω–∏–∑–º (–ì–† –∏–Ω—Å—É–ª–∏–Ω–æ—Ä–µ–∑–∏—Å—Ç–µ–Ω—Ç–µ–Ω), –Ω–æ —Å–∏–Ω–µ—Ä–≥–∏—è –≤ –∞–Ω–∞–±–æ–ª–∏–∑–º–µ
- **–ò–Ω—Å—É–ª–∏–Ω + –∫–æ—Ä—Ç–∏–∫–æ—Å—Ç–µ—Ä–æ–∏–¥—ã** ‚Üí –∞–Ω—Ç–∞–≥–æ–Ω–∏–∑–º (–∫–æ—Ä—Ç–∏–∑–æ–ª –ø–æ–≤—ã—à–∞–µ—Ç –≥–ª—é–∫–æ–∑—É)
- **–ò–Ω—Å—É–ª–∏–Ω + –ò–ì–§-1** ‚Üí —Å–∏–Ω–µ—Ä–≥–∏—á–µ—Å–∫–∞—è –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—è

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—è, –∞–ª–ª–µ—Ä–≥–∏—è –Ω–∞ –∏–Ω—Å—É–ª–∏–Ω –ª–∏–∑–ø—Ä–æ
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** –ø–æ—á–µ—á–Ω–∞—è/–ø–µ—á—ë–Ω–æ—á–Ω–∞—è –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å (—Å–Ω–∏–∂–µ–Ω–∏–µ –∫–ª–∏—Ä–µ–Ω—Å–∞ ‚Üí –ø—Ä–æ–ª–æ–Ω–≥–∏—Ä–æ–≤–∞–Ω–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç ‚Üí –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—è)

### Practical Notes (–∫–æ–Ω—Ç–µ–∫—Å—Ç –±–æ–¥–∏–±–∏–ª–¥–∏–Ω–≥–∞)
- **‚ö†Ô∏è –°–ê–ú–´–ô –û–ü–ê–°–ù–´–ô –ü–†–ï–ü–ê–†–ê–¢ –í –ë–û–î–ò–ë–ò–õ–î–ò–ù–ì–ï ‚Äî –ï–ñ–ï–ì–û–î–ù–û –ì–ò–ë–ù–£–¢ –õ–Æ–î–ò**
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ (–±–æ–¥–∏–±–∏–ª–¥–∏–Ω–≥):** –Ω–∞—á–∞–ª–æ 5 –ú–ï, —Ç–∏—Ç—Ä–∞—Ü–∏—è –ø–æ 1 –ú–ï, –ú–ê–ö–° 10‚Äì15 –ú–ï
- **–ü—Ä–∞–≤–∏–ª–æ 10 –≥:** –Ω–∞ –∫–∞–∂–¥—É—é 1 –ú–ï –∏–Ω—Å—É–ª–∏–Ω–∞ ‚Äî 10 –≥ —É–≥–ª–µ–≤–æ–¥–æ–≤ –≤ —Ç–µ—á–µ–Ω–∏–µ 15 –º–∏–Ω
- –ò–Ω—ä–µ–∫—Ü–∏—è –ø/–∫ ‚Üí —Å—Ä–∞–∑—É –Ω–∞—á–∞—Ç—å –ø—Ä–∏—ë–º –ø–∏—â–∏ (–±—ã—Å—Ç—Ä—ã–µ —É–≥–ª–µ–≤–æ–¥—ã + –±–µ–ª–æ–∫)
- –ü—Ä–∏ —Å—Ç–µ–∫–µ —Å –ì–†: –∏–Ω—Å—É–ª–∏–Ω –∫–æ–º–ø–µ–Ω—Å–∏—Ä—É–µ—Ç –∏–Ω—Å—É–ª–∏–Ω–æ—Ä–µ–∑–∏—Å—Ç–µ–Ω—Ç–Ω–æ—Å—Ç—å –æ—Ç –ì–†
- **–•—Ä–∞–Ω–µ–Ω–∏–µ:** –≤ —Ö–æ–ª–æ–¥–∏–ª—å–Ω–∏–∫–µ 2‚Äì8¬∞C, –ø–æ—Å–ª–µ –≤—Å–∫—Ä—ã—Ç–∏—è ‚Äî –ø—Ä–∏ –∫–æ–º–Ω–∞—Ç–Ω–æ–π —Ç–µ–º–ø–µ—Ä–∞—Ç—É—Ä–µ –¥–æ 28 –¥–Ω–µ–π
- **–ú–µ—Å—Ç–∞ –∏–Ω—ä–µ–∫—Ü–∏–π:** –∂–∏–≤–æ—Ç (–±—ã—Å—Ç—Ä–µ–µ –≤—Å–µ–≥–æ), –±–µ–¥—Ä–æ, –ø–ª–µ—á–æ ‚Äî —Ä–æ—Ç–∞—Ü–∏—è –º–µ—Å—Ç
- –õ–∏–ø–æ–¥–∏—Å—Ç—Ä–æ—Ñ–∏—è –ø—Ä–∏ –ø–æ–≤—Ç–æ—Ä–Ω—ã—Ö –∏–Ω—ä–µ–∫—Ü–∏—è—Ö –≤ –æ–¥–Ω–æ –º–µ—Å—Ç–æ

---

## –ê–ì–û–ù–ò–°–¢–´ –î–û–§–ê–ú–ò–ù–ê (DOPAMINE AGONISTS)

---

## 8. –ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω (Cabergoline / Dostinex)

### Mechanism of Action
- **–ú–æ—â–Ω—ã–π —Å–µ–ª–µ–∫—Ç–∏–≤–Ω—ã–π –∞–≥–æ–Ω–∏—Å—Ç D2-–¥–æ—Ñ–∞–º–∏–Ω–æ–≤—ã—Ö —Ä–µ—Ü–µ–ø—Ç–æ—Ä–æ–≤** ‚Äî –ø—Ä–æ–∏–∑–≤–æ–¥–Ω–æ–µ —ç—Ä–≥–æ—Ç–∞–º–∏–Ω–∞
- D2S: Ki = 0.5‚Äì0.62 nM, Emax 102% (—Å—É–ø–µ—Ä–∞–≥–æ–Ω–∏—Å—Ç!)
- D2L: Ki = 0.95 nM, Emax 75% (–ø–∞—Ä—Ü–∏–∞–ª—å–Ω—ã–π –∞–≥–æ–Ω–∏—Å—Ç)
- D3: Ki = 0.80‚Äì1.0 nM, Emax 86% (–ø–æ–ª–Ω—ã–π –∞–≥–æ–Ω–∏—Å—Ç)
- –¢–∞–∫–∂–µ –∑–Ω–∞—á–∏—Ç–µ–ª—å–Ω–æ–µ —Å—Ä–æ–¥—Å—Ç–≤–æ –∫: 5-HT1A (Ki 1.9‚Äì20), 5-HT2A (Ki 4.6‚Äì6.2), 5-HT2B (Ki 1.2‚Äì9.4), Œ±2-–∞–¥—Ä–µ–Ω–æ—Ä–µ—Ü–µ–ø—Ç–æ—Ä—ã (Ki 12‚Äì132)
- –ü—Ä—è–º–æ–µ –∏–Ω–≥–∏–±–∏—Ä–æ–≤–∞–Ω–∏–µ —Å–µ–∫—Ä–µ—Ü–∏–∏ –ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–∞ –ª–∞–∫—Ç–æ—Ç—Ä–æ—Ñ–Ω—ã–º–∏ –∫–ª–µ—Ç–∫–∞–º–∏ –≥–∏–ø–æ—Ñ–∏–∑–∞
- –ü–µ—Ä–∏–æ–¥ –ø–æ–ª—É–≤—ã–≤–µ–¥–µ–Ω–∏—è: **63‚Äì69 —á–∞—Å–æ–≤** (–æ—á–µ–Ω—å –¥–ª–∏–Ω–Ω—ã–π ‚Äî –¥–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ 1‚Äì2 —Ä–∞–∑–∞/–Ω–µ–¥–µ–ª—é)
- –ë–∏–æ–¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å: 50‚Äì80%
- –ú–µ—Ç–∞–±–æ–ª–∏–∑–º: –ø–µ—á–µ–Ω—å (–≥–∏–¥—Ä–æ–ª–∏–∑ –∞—Ü–∏–ª–º–æ—á–µ–≤–∏–Ω–Ω–æ–π —Å–≤—è–∑–∏)

### Key Clinical Studies
- **Schade R et al., 2007** (PMID: verify ‚Äî NEJM Jan 4, 2007)
  - Design: Case-control study
  - Key finding: –ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω –∏ –ø–µ—Ä–≥–æ–ª–∏–¥ –∞—Å—Å–æ—Ü–∏–∏—Ä–æ–≤–∞–Ω—ã —Å –∫–ª–∞–ø–∞–Ω–Ω–æ–π –±–æ–ª–µ–∑–Ω—å—é —Å–µ—Ä–¥—Ü–∞ –ø—Ä–∏ –≤—ã—Å–æ–∫–∏—Ö –¥–æ–∑–∞—Ö (–ü–∞—Ä–∫–∏–Ω—Å–æ–Ω)
  - Relevance: –ü—Ä–∏–≤–µ–ª–æ –∫ —Å–Ω—è—Ç–∏—é –ø–µ—Ä–≥–æ–ª–∏–¥–∞ —Å —Ä—ã–Ω–∫–∞. –ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω –æ—Å—Ç–∞–ª—Å—è ‚Äî –¥–æ–∑—ã –ø—Ä–∏ –≥–∏–ø–µ—Ä–ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–µ–º–∏–∏ –±–µ–∑–æ–ø–∞—Å–Ω—ã
- **Colao A et al., 2008** (PMID: verify)
  - Design: Observational study
  - Key finding: –î–æ–∑—ã –∫–∞–±–µ—Ä–≥–æ–ª–∏–Ω–∞ –¥–ª—è –ª–µ—á–µ–Ω–∏—è –≥–∏–ø–µ—Ä–ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–µ–º–∏–∏ –ù–ï –∞—Å—Å–æ—Ü–∏–∏—Ä–æ–≤–∞–Ω—ã —Å –∫–ª–∏–Ω–∏—á–µ—Å–∫–∏ –∑–Ω–∞—á–∏–º–æ–π –∫–ª–∞–ø–∞–Ω–Ω–æ–π –±–æ–ª–µ–∑–Ω—å—é
  - Relevance: –ë–µ–∑–æ–ø–∞—Å–Ω–æ—Å—Ç—å –ø—Ä–∏ —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã—Ö –¥–æ–∑–∞—Ö
- **–°–∏—Å—Ç–µ–º–∞—Ç–∏—á–µ—Å–∫–∏–π –æ–±–∑–æ—Ä –∏ –º–µ—Ç–∞-–∞–Ω–∞–ª–∏–∑** (–∏–∑ Wikipedia)
  - Key finding: –ü—Ä–æ—Ñ–∏–ª–∞–∫—Ç–∏—á–µ—Å–∫–∏–π –∫–∞–±–µ—Ä–≥–æ–ª–∏–Ω —Å–Ω–∏–∂–∞–µ—Ç —á–∞—Å—Ç–æ—Ç—É (–Ω–æ –Ω–µ —Ç—è–∂–µ—Å—Ç—å) OHSS –ø—Ä–∏ –≠–ö–û

### Bloodwork Markers to Monitor
- **–ü—Ä–æ–ª–∞–∫—Ç–∏–Ω** ‚Äî –∫–∞–∂–¥—ã–µ 4‚Äì8 –Ω–µ–¥–µ–ª—å (–æ—Å–Ω–æ–≤–Ω–æ–π –º–∞—Ä–∫—ë—Ä)
- **–≠—Ö–æ–∫–∞—Ä–¥–∏–æ–≥—Ä–∞—Ñ–∏—è** ‚Äî –∫–∞–∂–¥—ã–µ 6‚Äì12 –º–µ—Å—è—Ü–µ–≤ (–∫–ª–∞–ø–∞–Ω–Ω–∞—è —Ä–µ–≥—É—Ä–≥–∏—Ç–∞—Ü–∏—è, –æ—Å–æ–±–µ–Ω–Ω–æ –ø—Ä–∏ –≤—ã—Å–æ–∫–∏—Ö –¥–æ–∑–∞—Ö)
- **–ü–µ—á—ë–Ω–æ—á–Ω—ã–µ —Ñ–µ—Ä–º–µ–Ω—Ç—ã (–ê–õ–¢, –ê–°–¢)** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–ö—Ä–µ–∞—Ç–∏–Ω–∏–Ω** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞
- **–û–±—â–∏–π –∞–Ω–∞–ª–∏–∑ –∫—Ä–æ–≤–∏** ‚Äî –∫–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞ (—Ä–µ–¥–∫–∏–µ –≥–µ–º–∞—Ç–æ–ª–æ–≥–∏—á–µ—Å–∫–∏–µ —ç—Ñ—Ñ–µ–∫—Ç—ã)
- **–ê–î** ‚Äî —Ä–µ–≥—É–ª—è—Ä–Ω–æ (–≥–∏–ø–æ—Ç–µ–Ω–∑–∏—è ‚Äî —á–∞—Å—Ç—ã–π –ø–æ–±–æ—á–Ω—ã–π —ç—Ñ—Ñ–µ–∫—Ç)
- **–°–û–≠ / —Ä–µ–Ω—Ç–≥–µ–Ω –ª—ë–≥–∫–∏—Ö** ‚Äî –ø—Ä–∏ –¥–ª–∏—Ç–µ–ª—å–Ω–æ–º –ø—Ä–∏—ë–º–µ (–ø–ª–µ–≤—Ä–∞–ª—å–Ω—ã–π/–ª—ë–≥–æ—á–Ω—ã–π —Ñ–∏–±—Ä–æ–∑)

### Drug Interactions
- **–ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω + –∞–Ω—Ç–∞–≥–æ–Ω–∏—Å—Ç—ã –¥–æ—Ñ–∞–º–∏–Ω–∞ (–∞–Ω—Ç–∏–ø—Å–∏—Ö–æ—Ç–∏–∫–∏, –º–µ—Ç–æ–∫–ª–æ–ø—Ä–∞–º–∏–¥)** ‚Üí –≤–∑–∞–∏–º–Ω–∞—è –Ω–µ–π—Ç—Ä–∞–ª–∏–∑–∞—Ü–∏—è
- **–ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω + –∞–Ω—Ç–∏–≥–∏–ø–µ—Ä—Ç–µ–Ω–∑–∏–≤–Ω—ã–µ** ‚Üí —á—Ä–µ–∑–º–µ—Ä–Ω–∞—è –≥–∏–ø–æ—Ç–µ–Ω–∑–∏—è
- **–ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω + –¥—Ä—É–≥–∏–µ –ø—Ä–æ–∏–∑–≤–æ–¥–Ω—ã–µ —ç—Ä–≥–æ—Ç–∞–º–∏–Ω–∞** ‚Üí –ù–ï –∫–æ–º–±–∏–Ω–∏—Ä–æ–≤–∞—Ç—å
- **–ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω + –∏–Ω–≥–∏–±–∏—Ç–æ—Ä—ã CYP450 (—ç—Ä–∏—Ç—Ä–æ–º–∏—Ü–∏–Ω, –∫–µ—Ç–æ–∫–æ–Ω–∞–∑–æ–ª)** ‚Üí –ø–æ–≤—ã—à–µ–Ω–∏–µ —É—Ä–æ–≤–Ω—è –∫–∞–±–µ—Ä–≥–æ–ª–∏–Ω–∞ (—Ö–æ—Ç—è –º–∏–Ω–∏–º–∞–ª—å–Ω–æ –º–µ—Ç–∞–±–æ–ª–∏–∑–∏—Ä—É–µ—Ç—Å—è CYP)
- –ù–µ—Ç –∑–Ω–∞—á–∏–º—ã—Ö –≤–∑–∞–∏–º–æ–¥–µ–π—Å—Ç–≤–∏–π —Å –ª–µ–≤–æ–¥–æ–ø–æ–π –∏ —Å–µ–ª–µ–≥–∏–ª–∏–Ω–æ–º

### Contraindications
- **–ê–±—Å–æ–ª—é—Ç–Ω—ã–µ:** –≥–∏–ø–µ—Ä—á—É–≤—Å—Ç–≤–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å –∫ –ø—Ä–æ–∏–∑–≤–æ–¥–Ω—ã–º —Å–ø–æ—Ä—ã–Ω—å–∏, —Ç—è–∂—ë–ª–∞—è –ø–µ—á—ë–Ω–æ—á–Ω–∞—è –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ—Å—Ç—å, —Ö–æ–ª–µ—Å—Ç–∞–∑, –¥–µ—Ç–∏
- **–û—Ç–Ω–æ—Å–∏—Ç–µ–ª—å–Ω—ã–µ:** —Ç—è–∂—ë–ª—ã–µ –°–°–ó, –±–æ–ª–µ–∑–Ω—å –†–µ–π–Ω–æ, —è–∑–≤–µ–Ω–Ω–∞—è –±–æ–ª–µ–∑–Ω—å, –∞–∫—Ç–∏–≤–Ω–æ–µ –ì–ò –∫—Ä–æ–≤–æ—Ç–µ—á–µ–Ω–∏–µ, –≥–∏–ø–æ—Ç–µ–Ω–∑–∏—è, –±–µ—Ä–µ–º–µ–Ω–Ω–æ—Å—Ç—å (–±—Ä–æ–º–æ–∫—Ä–∏–ø—Ç–∏–Ω –ø—Ä–µ–¥–ø–æ—á—Ç–∏—Ç–µ–ª—å–Ω–µ–µ)

### Practical Notes
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ (–≥–∏–ø–µ—Ä–ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–µ–º–∏—è):** 0.25 –º–≥ 2 —Ä–∞–∑–∞/–Ω–µ–¥–µ–ª—é ‚Üí —Ç–∏—Ç—Ä–∞—Ü–∏—è –ø–æ 0.25 –º–≥ –∫–∞–∂–¥—ã–µ 2‚Äì4 –Ω–µ–¥–µ–ª–∏ ‚Üí –æ–±—ã—á–Ω–∞—è –¥–æ–∑–∞ 0.5‚Äì1 –º–≥/–Ω–µ–¥–µ–ª—é
- **–î–æ–∑–∏—Ä–æ–≤–∞–Ω–∏–µ (–±–æ–¥–∏–±–∏–ª–¥–∏–Ω–≥, –∫–æ–Ω—Ç—Ä–æ–ª—å –ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–∞ –Ω–∞ 19-–Ω–æ—Ä —Å—Ç–µ—Ä–æ–∏–¥–∞—Ö):** 0.25‚Äì0.5 –º–≥ 2 —Ä–∞–∑–∞/–Ω–µ–¥–µ–ª—é
  - 19-–Ω–æ—Ä —Å—Ç–µ—Ä–æ–∏–¥—ã (–Ω–∞–Ω–¥—Ä–æ–ª–æ–Ω, —Ç—Ä–µ–Ω–±–æ–ª–æ–Ω) –ø–æ–≤—ã—à–∞—é—Ç –ø—Ä–æ–ª–∞–∫—Ç–∏–Ω ‚Üí –≥–∏–Ω–µ–∫–æ–º–∞—Å—Ç–∏—è, "–¥–µ–∫–∞-–¥–∏–∫", –ª–∞–∫—Ç–∞—Ü–∏—è
  - –ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω ‚Äî —Å—Ç–∞–Ω–¥–∞—Ä—Ç –∫–æ–Ω—Ç—Ä–æ–ª—è –ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–∞ –≤ PED
- **–ú–µ–¥–ª–µ–Ω–Ω–∞—è —Ç–∏—Ç—Ä–∞—Ü–∏—è** –æ–±—è–∑–∞—Ç–µ–ª—å–Ω–∞ (2‚Äì4 –Ω–µ–¥–µ–ª–∏ –Ω–∞ —à–∞–≥)
- –ü–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã –≤ —Ü–µ–ª–æ–º –º—è–≥–∫–∏–µ –ø—Ä–∏ –¥–æ–∑–∞—Ö –¥–ª—è –≥–∏–ø–µ—Ä–ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–µ–º–∏–∏ (–≤ 10‚Äì100 —Ä–∞–∑ –Ω–∏–∂–µ —á–µ–º –ø—Ä–∏ –ü–∞—Ä–∫–∏–Ω—Å–æ–Ω–µ)
- –ü—Ä–µ–¥–ø–æ—á—Ç–∏—Ç–µ–ª—å–Ω–µ–µ –±—Ä–æ–º–æ–∫—Ä–∏–ø—Ç–∏–Ω–∞: –≤—ã—à–µ –∞—Ñ—Ñ–∏–Ω–Ω–æ—Å—Ç—å D2, —É–¥–æ–±–Ω–µ–µ —Å—Ö–µ–º–∞, –ª—É—á—à–µ –ø–µ—Ä–µ–Ω–æ—Å–∏–º–æ—Å—Ç—å
- –ü—Ä–∏ –≤—ã—Å–æ–∫–∏—Ö –¥–æ–∑–∞—Ö (–ü–∞—Ä–∫–∏–Ω—Å–æ–Ω): 76% –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ –æ—Ç–º–µ—á–∞—é—Ç –ø–æ–±–æ—á–Ω—ã–µ —ç—Ñ—Ñ–µ–∫—Ç—ã (–ì–ò, –¶–ù–°, –°–°–°)
- –ö–ª–∞–ø–∞–Ω–Ω–∞—è –±–æ–ª–µ–∑–Ω—å: **—Ä–∏—Å–∫ –ø—Ä–∏ –¥–æ–∑–∞—Ö –¥–ª—è –ü–∞—Ä–∫–∏–Ω—Å–æ–Ω–∞, –ù–ï –ø—Ä–∏ –¥–æ–∑–∞—Ö –¥–ª—è –ø—Ä–æ–ª–∞–∫—Ç–∏–Ω–µ–º–∏–∏**
- –£–º–µ–Ω—å—à–µ–Ω–∏–µ –º—É–∂—Å–∫–æ–≥–æ —Ä–µ—Ñ—Ä–∞–∫—Ç–µ—Ä–Ω–æ–≥–æ –ø–µ—Ä–∏–æ–¥–∞ ‚Äî –ø–æ–¥—Ç–≤–µ—Ä–∂–¥–µ–Ω–æ –≤ 2 –Ω–∞—É—á–Ω—ã—Ö –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è—Ö
- –õ—ë–≥–æ—á–Ω—ã–π/–ø–ª–µ–≤—Ä–∞–ª—å–Ω—ã–π —Ñ–∏–±—Ä–æ–∑: <2%, –Ω–µ–º–µ–¥–ª–µ–Ω–Ω–∞—è –æ—Ç–º–µ–Ω–∞, –Ω–æ—Ä–º–∞–ª–∏–∑–∞—Ü–∏—è –ø–æ—Å–ª–µ –ø—Ä–µ–∫—Ä–∞—â–µ–Ω–∏—è

---

## –ü–µ—Ä–µ–∫—Ä—ë—Å—Ç–Ω—ã–µ –≤–∑–∞–∏–º–æ–¥–µ–π—Å—Ç–≤–∏—è –º–µ–∂–¥—É –∫–∞—Ç–µ–≥–æ—Ä–∏—è–º–∏

| –ö–æ–º–±–∏–Ω–∞—Ü–∏—è | –†–∏—Å–∫ | –û–ø–∏—Å–∞–Ω–∏–µ |
|-----------|------|----------|
| **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + –≠—Ñ–µ–¥—Ä–∏–Ω** | üî¥ –ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô | –ê–¥–¥–∏—Ç–∏–≤–Ω–∞—è Œ≤-—Å—Ç–∏–º—É–ª—è—Ü–∏—è, –∞—Ä–∏—Ç–º–∏—è, –∏–Ω—Ñ–∞—Ä–∫—Ç |
| **–ö–ª–µ–Ω–±—É—Ç–µ—Ä–æ–ª + T3** | üî¥ –ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô | –°–∏–Ω–µ—Ä–≥–∏—á–µ—Å–∫–∞—è –∫–∞—Ä–¥–∏–æ—Ç–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å |
| **–≠—Ñ–µ–¥—Ä–∏–Ω + T3** | üî¥ –ö–†–ò–¢–ò–ß–ï–°–ö–ò–ô | FDA Black Box Warning |
| **–õ—é–±–æ–π —Å—Ç–∏–º—É–ª—è—Ç–æ—Ä + –ô–æ—Ö–∏–º–±–∏–Ω** | üü° –í–´–°–û–ö–ò–ô | –ê–¥–¥–∏—Ç–∏–≤–Ω–∞—è –∞–¥—Ä–µ–Ω–µ—Ä–≥–∏—á–µ—Å–∫–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è |
| **–ò–Ω—Å—É–ª–∏–Ω + T3** | üü° –í–´–°–û–ö–ò–ô | T3 –ø–æ–≤—ã—à–∞–µ—Ç –≥–ª—é–∫–æ–∑—É ‚Üí –Ω—É–∂–Ω–æ –±–æ–ª—å—à–µ –∏–Ω—Å—É–ª–∏–Ω–∞ ‚Üí —Ä–∏—Å–∫ –ø–µ—Ä–µ–¥–æ–∑–∏—Ä–æ–≤–∫–∏ |
| **–ò–Ω—Å—É–ª–∏–Ω + –°–µ–º–∞–≥–ª—É—Ç–∏–¥/–¢–∏—Ä–∑–µ–ø–∞—Ç–∏–¥** | üü° –í–´–°–û–ö–ò–ô | –°—É–º–º–∞—Ü–∏—è –≥–∏–ø–æ–≥–ª–∏–∫–µ–º–∏—á–µ—Å–∫–æ–≥–æ —ç—Ñ—Ñ–µ–∫—Ç–∞ |
| **–ö–∞–±–µ—Ä–≥–æ–ª–∏–Ω + –∞–Ω—Ç–∏–ø—Å–∏—Ö–æ—Ç–∏–∫–∏** | üü° –°–†–ï–î–ù–ò–ô | –í–∑–∞–∏–º–Ω–∞—è –Ω–µ–π—Ç—Ä–∞–ª–∏–∑–∞—Ü–∏—è |
| **–°–µ–º–∞–≥–ª—É—Ç–∏–¥ + –ø–µ—Ä–æ—Ä–∞–ª—å–Ω—ã–µ –ø—Ä–µ–ø–∞—Ä–∞—Ç—ã** | üü° –°–†–ï–î–ù–ò–ô | –ó–∞–º–µ–¥–ª–µ–Ω–∏–µ –∞–±—Å–æ—Ä–±—Ü–∏–∏ |

---

> **–î–ò–°–ö–õ–ï–ô–ú–ï–†:** –î–∞–Ω–Ω—ã–π –¥–æ–∫—É–º–µ–Ω—Ç –Ω–æ—Å–∏—Ç –∏—Å–∫–ª—é—á–∏—Ç–µ–ª—å–Ω–æ –∏–Ω—Ñ–æ—Ä–º–∞—Ü–∏–æ–Ω–Ω—ã–π —Ö–∞—Ä–∞–∫—Ç–µ—Ä –¥–ª—è –ø—Ä–æ–µ–∫—Ç–∞ BloodTracker. –ò—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ –ª—é–±—ã—Ö –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤ –¥–æ–ª–∂–Ω–æ –æ—Å—É—â–µ—Å—Ç–≤–ª—è—Ç—å—Å—è –ø–æ–¥ –Ω–∞–±–ª—é–¥–µ–Ω–∏–µ–º –∫–≤–∞–ª–∏—Ñ–∏—Ü–∏—Ä–æ–≤–∞–Ω–Ω–æ–≥–æ –≤—Ä–∞—á–∞. –ò–Ω—Å—É–ª–∏–Ω —è–≤–ª—è–µ—Ç—Å—è –ü–û–¢–ï–ù–¶–ò–ê–õ–¨–ù–û –°–ú–ï–†–¢–ï–õ–¨–ù–´–ú –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–º –¥–∞–∂–µ –ø—Ä–∏ –Ω–µ–∑–Ω–∞—á–∏—Ç–µ–ª—å–Ω–æ–π –ø–µ—Ä–µ–¥–æ–∑–∏—Ä–æ–≤–∫–µ.
